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                                                        ABSTRACT 
 
ACINETOBACTER BAUMANNII: AN EVALUATION OF FIVE SUSCEPTIBILITY TEST 
METHODS TO DETECT TOBRAMYCIN RESISTANCE IN AN EPIDEMIOLOGICALLY 
RELATED CLUSTER. 
 
V. Mischka Moodley 1, 2, Stephen P. Oliver 1, 2, Iva Shankland 2, and B. Gay Elisha 1, 2 
 
1Division of Medical Microbiology, Clinical Laboratory Sciences Faculty, University of 
Cape Town 
2Groote Schuur Hospital, National Health Laboratory Services, South Africa 
 
Abstract 
 
BACKGROUND 
Acinetobacter baumannii is a major pathogen causing nosocomial infections, particularly 
in critically ill patients.  This organism has acquired the propensity to rapidly develop 
resistance to most antibiotics. At several hospitals within Cape Town, tobramycin and 
colistin remain frequently the only therapeutic options. The Vitek2 automated 
susceptibility testing (AST) is used in the clinical laboratory to determine selected 
susceptibility profiles. The suspicion of a possible AST-related technical error when 
testing for susceptibility to tobramycin in A. baumannii precipitated this study.  
 
METHODOLOGY 
Forty A. baumannii strains isolated from clinical specimens (June-December 2006) 
which exhibited MICs close to the tobramycin breakpoints were included in this 
prospective study. AST was compared to disk diffusion, Epsilometer test and agar 
dilution using broth microdilution (BMD) as the reference method. Additionally, PCR was 
performed to detect the aac(3)-II’ gene which encodes an aminoglycoside modifying 
enzyme with activity against tobramycin.  
 
RESULTS 
The tobramycin susceptibility results revealed errors in 25/39 isolates (10 very major 
and 15 minor errors) when AST was compared to BMD (p<0.001), 12/39 (1 very major 
and 11 minor errors) when Etest was compared to BMD, and 15 errors (3 very major 
and 12 minor errors) when disk diffusion was compared to BMD. Additionally, the 
tobramycin resistance gene, aac(3)-II,’ was detected in 21/25 of the discrepant isolates, 
confirming the resistant phenotype detected by the reference method. Molecular typing 
showed that these isolates were genetically related.  
 
CONCLUSION 
Clinical laboratories using the Vitek2 system for routine use should consider an 
alternative susceptibility testing method to determine susceptibility to tobramycin. 
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                                                 ABBREVIATIONS 
 
%                  percentage 
ºC                  degrees Celcius 
aac(3)-IIa      aminoglycoside acetyltransferase(3)-IIa gene 
AAC(3)-IIa    aminoglycoside acetyltransferase(3)-IIa enzyme 
AFLP            amplified fragment length polymorphism 
AME             aminoglycoside modifying enzyme 
AST              automated susceptibility testing 
ATCC           American Type Culture Collection 
BMD             broth microdilution 
CLSI             Clinical Laboratory Sciences Institute 
DNA              deoxyribonucleic acid  
ESBL            extended spectrum beta-lactamase 
ESI-MS         electrospray ionisation mass spectrophotometry 
Etest             epsilometric test 
GSH              Groote Schuur hospital 
hrs                 hours 
ICU                intensive Care Unit 
kb                  kilobase 
kDa               kiloDaltons 
NHLS            National Health Laboratory Services 
mcF              McFarland 
MDR             multidrug-resistant 
µg                  microgram 
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µl                   microliter 
mg                 milligram 
ml                  millilitre 
mM                millimoles 
mm                millimetre 
MIC               minimal inhibitory concentration 
ng                  nanogram 
PBP              penicillin-binding protein 
PCR              polymerase chain reaction 
PFGE            pulse field gel electrophoresis 
pmole            picomole 
OXA             oxacillinase 
rRNA            ribosomal RNA 
SANAS         South African National Accreditation Society 
SOP              standard operating procedure 
Taq               Thermus aquaticus 
TLR               Toll-like receptor 
U                   unit 
UK                 United Kingdom 
US                 United States of America 
UV                 ultraviolet 
V                   volts 
VAP               ventilator-associated pneumonia 
VME(s)          very major error(s) 
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RESEARCH PROPOSAL 
 
OBJECTIVE and AIMS: 
The overall objective of this study is to evaluate the Vitek®2 automated susceptibility 
testing system (bioMérieux, Durham, North Carolina) for tobramycin susceptibility 
testing of Acinetobacter baumannii using broth microdilution as the reference standard.  
  
Aims: 
1. To compare the Vitek®2 automated susceptibility testing with disc diffusion, 
Epsilometric test (E-test), agar dilution, and broth microdilution (reference standard) 
methodology for aminoglycoside susceptibility testing of A. baumannii in the diagnostic 
microbiology laboratory at Groote Schuur Hospital. 
 
2. To determine whether the choice of nutrient agar and bacterial cell inoculum used in 
the manual method and in the Vitek®2, respectively, impacts on the outcome of 
susceptibility testing. 
 
3. Determination of genetic relatedness of A. baumannii strains with discrepant Vitek®2/ 
broth microdilution tobramycin susceptibility results.  
 
4. Identification of the mechanism of tobramycin resistance in selected A. baumannii 
strains. 
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BACKGROUND 
Acinetobacter baumannii has emerged as a major nosocomial pathogen in many 
intensive care units throughout the world (1, 2, 5, 21, 24). These non-fastidious, strictly 
aerobic Gram-negative organisms present several problems. Firstly, Acinetobacter 
species are opportunistic organisms with the capacity for long-term survival in the 
hospital environment. The organism has the ability to colonize human skin, thereby 
contributing to cross-transmission in the hospital.  
Secondly, these organisms have been associated with fatal infections in critically ill 
patients. Acinetobacter has been implicated in bacteraemia, respiratory tract and 
surgical site infections.  Factors predisposing to infection include prolonged hospital 
stay, admission to an intensive care unit, mechanical ventilation, previous treatment with 
antimicrobials, invasive procedures or instrumentations, burns, immunosuppression, 
and previous sepsis (1, 2, 5, 12, 24). A. baumannii bacteraemia is associated with a 
high crude mortality rate (varying between 17 and 52%) and prolonged hospital stay (2, 
13, 15). Patient characteristics that play a major role in outcome include age, 
immunosuppression, recent surgery, acute respiratory failure, acute renal failure, septic 
shock, and appropriate choice of initial antibiotic therapy (6, 11). 
Thirdly, its intrinsic resistance to many antimicrobial agents as well as the propensity to 
develop resistance to newly developed antibiotics has made A. baumannii a formidable 
adversary. It is of great concern that the incidence of carbapenem-resistant 
acinetobacter isolates is increasing. Measures to limit the spread include enforcement of 
hand washing, sterilization of ventilator equipment,  dedication of equipment to 
individual patients, use of isolation facilities, restriction of antibiotic usage, and ward 
closure (5, 12). The choice of available antibiotics, however, grows more limited.  In 
multi-resistant  acinetobacter infections,  some remaining  options include polymyxins 
(colistin),  sulbactam and tigecycline (1). Known resistance mechanisms of A. 
baumannii to antimicrobials are the production of broad-spectrum β−lactamases, 
carbapenemases, aminoglycoside-modifying enzymes, mutations in outer membrane 
porins, and alterations in penicillin-binding proteins. As therapeutic possibilities 
decrease, patient mortality increases due to inappropriate empiric antimicrobial 
treatment.   
Accurate identification of Gram-negative non-fermenters in the clinical laboratory relies 
mainly on automated or semi-automated systems. These systems have the advantages 
of decreasing laboratory turn-around time, perceived cost-effectiveness, and are able to 
be interfaced to laboratory and hospital information systems. Unfortunately, they have 
limitations. Numerous studies have reported on errors in the accuracy of various  
automated systems in identification and sensitivity testing especially amongst the non-
fermenters (14, 16). 
A. baumannii is endemic in some hospitals’ intensive care units within the Cape Town 
metropole. The majority of these isolates are multi-resistant organisms, only remaining 
susceptible to tobramycin and colistin. Surveillance data collected by the National 
Antibiotic Surveillance Forum in 2006 revealed that of the 161 blood culture isolates of 
A. baumannii cultured at Groote Schuur Hospital (a tertiary academic institution), 57% 
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were susceptible to piperacillin-tazobactam and ciprofloxacin, while 42% were 
susceptible to ceftazidime. Importantly, only 55% and 57% were susceptible to the 
carbapenems, imipenem and meropenem, respectively (17). Similar rates of resistance 
are seen at other hospitals in South Africa (see Table 1).  
 
TABLE 1: Susceptibility rates for Acinetobacter species isolated from blood from clinical 
diagnostic laboratories in different provinces of South Africa in 2006 (17).
 
LABORATORY TOTAL 
NUMBER 
OF 
ISOLATES 
PITZ CIPRO CTAZ IMI MERO 
Gauteng 
Chris Hani 
Baragwaneth 
132 85% 50% 51% 69% 71% 
Charlotte Maxeke 
Johannesburg 
Academic 
70 56% 51% 53% 51% 53% 
Dr George 
Mukhari  
61 62% 56% 75% 49% 51% 
Tshwane 
Pretoria Academic 40 80% 63% 65% 68% 68% 
Western Cape 
Groote Schuur 161 57% 57% 42% 55% 57% 
Tygerberg 124 80% 79% 74% 77% 77% 
 
Note: PITZ-piperacillin-tazobactam, CIPRO-ciprofloxacin, CTAZ-ceftazidime, IMI-imipenem, MERO-
meropenem 
 
With respect to aminoglycoside sensitivity, statistics show that of the A. baumannii 
isolated in the diagnostic laboratory at Groote Schuur Hospital, from all clinical 
specimens during the period 1/10/2005-30/09/2006, 82.75% of 1125 acinetobacter 
isolates were resistant to gentamicin, 71.63% of 1195 isolates were resistant to 
amikacin, and 42.29 % of 1206 isolates were resistant to tobramycin (NHLS Laboratory 
Information System). An increasing number of Vitek®2 reports were being sent out from 
the laboratory noting A. baumannii isolates with MICs close to the tobramycin 
breakpoints (CLSI breakpoints). Further, an inconsistency between the antibiograms, as 
detected by disc diffusion and Etest strips, and the Vitek®2 automated susceptibility 
testing was noted. These discrepancies drew our attention to possible technical 
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problems with the current Vitek®2 system. In this context, an extensive literature search 
and discussions with bioMérieux indicated that problems with tobramycin susceptibility 
testing of A. baumannii had not been reported previously.  
The following study, to evaluate the accuracy of the Vitek®2 automated susceptibility 
testing for aminoglycoside antibiotics, was predicated by the limited therapeutic options 
and the consequences of initiating septic patients on inappropriate therapy. 
 
METHODOLOGY 
Seventy-eight isolates were collected from specimens sent to the clinical diagnostic 
microbiology laboratory during a seven month period (June 2006 – December 2006). 
Technologists at our laboratory were requested to make single colony plates of A. 
baumannii from clinical isolates with MICs/disc zone sizes close to the CLSI breakpoints 
for tobramycin (4). These isolates were specifically chosen as we had noted 
discrepancies between the Vitek®2 and Etests in this group previously. A few fully 
sensitive and resistant isolates were also chosen to evaluate the complete range of 
isolates analysed by the Vitek®2 in the clinical diagnostic laboratory. Duplicate 
specimens from the same patient were avoided except where the sensitivity pattern to 
aminoglycosides changed. 
The majority of the isolates were obtained from sputum, blood culture, pus swabs, 
tissue culture and urine specimens of ICU patients (medical, surgical and  paediatric 
ICUs from four hospitals), including three pus swabs taken during a  surveillance 
exercise of the ICUs (See Table 3, Part D). The remainder of the isolates were obtained 
from patients in the general wards. Groote Schuur Hospital and Red Cross Children’s 
Hospital represent tertiary academic institutions, with Mowbray Maternity Hospital, G.F. 
Jooste and Victoria Hospital being secondary level institutions.  
All isolates will be inoculated on to fresh MacConkey agar to obtain single colonies that 
will be utilized for identification and susceptibility testing. 
Storage 
The agar plates will be stored at 4 ºC. Single colony plates will be sub-cultured if 
necessary (maximum twice) to ensure viability of the organisms. Following susceptibility 
testing, all isolates will be stored on beads at -70 ºC (Viabank VIM tubes, ABTEK 
Biologicals Ltd, Liverpool). Recovery of organisms from beads will be performed 
according to the manufacturer’s instructions.  
 
IDENTIFICATION OF BACTERIA 
The identification of the isolates will be confirmed as per standard laboratory protocol 
and manufacturer’s instruction using the Vitek®2 system (See SOP 1, Part D).  
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Introduction 
The Vitek®2 Gram-Negative Identification Card (GN-ID) intended for the automatic 
identification of significant fermenting and non-fermenting gram-negative bacteria, 
utilises the results of 41 biochemical tests to identify an isolate. The results of the 
biochemical tests are compared to the expected corresponding set of reactions for each 
organism. A qualitative value (percentage probability) is calculated based on the 
observed test reactions versus the typical reactions for each organism. Thus, a perfect 
match would provide a percentage probability of 99%. A percentage probability of 85-
97% indicates that a test reaction pattern is sufficiently close to the biochemical profile 
of a particular organism or organism group. Results are usually available within 3 hours. 
 
Methodology 
Fresh isolates (18-24 hours old) will be identified using the Vitek®2 system (See 
Standard Operating Procedure 1, Part D). An isolated colony from the single colony 
plate will be selected and emulsified in sterile saline in a clear plastic tube to obtain a 
density of 0.6 and 1.0 McFarland, respectively. Cassettes with tubes and cards will be 
loaded into the Vitek®2 according to the manufacturer’s instructions. 
The identification of each isolate will be confirmed twice, at 0.6 McFarland 
(manufacturer’s recommendation) and 1.0 McFarland, respectively. Only Vitek®2 
results with a percentage probability above 94 % (Very Good, Excellent Identification 
categories) will be considered as acceptable identifications. 
The identification of each isolate will also be confirmed independently by the bioMérieux 
Research and Development Division using API phenotypic testing panels. 
 
ANTIBIOTIC SUSCEPTIBILITY 
Antibiotic susceptibility testing will be performed on all isolates. The following methods 
will be employed: disc diffusion; MIC determination by Etests, agar dilution and broth 
microdilution; and automated susceptibility testing by Vitek®2.  
 
Disc diffusion 
Introduction 
Disc diffusion is one of the most popular methods of antimicrobial susceptibility testing 
due to its ease of use and low cost. This method is based on the diffusion through agar 
of an antimicrobial drug released from an impregnated disc. When a disc is applied to 
the agar surface, the antibiotic begins to diffuse immediately. This results in a 
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concentration gradient that diminishes with distance from the edge of the disc. The zone 
edge is formed by the growth of the organism at the point in the agar where the 
antibiotic concentration is at the critical concentration, which is defined as the 
concentration that is just capable of inhibiting bacterial growth. Unlike other dilution 
methods, an MIC value is not generated. Instead, a zone diameter is used to predict an 
MIC value, and which category of susceptibility the strain belongs to. 
Several factors can influence the result of disc diffusion testing. These include the disc 
content (amount of drug per disc), the diffusion characteristics of the drug, the disc size, 
the depth of the agar, the density of the inoculum, and incubation time (10, 23). To 
ensure standardization, commercial media obtained from three different manufacturers 
will be used in the study. In addition, antibiotic discs with the same lot numbers will be 
used, and a mechanical rotary device will be used to distribute the bacterial inoculum 
evenly across the agar surface. Quality control will be performed for each batch of 
media used. 
 
Methodology 
Disc diffusion testing (modified Bauer-Kirby method) will be performed in accordance 
with CLSI standards (3, 4). Cation-adjusted Mueller-Hinton media will be utilised for the 
disc diffusion testing. The disc diffusion will be performed in triplicate on three different 
commercial media [bioMérieux (Randburg, South Africa), Bio-Rad Laboratories 
(Johannesburg, South Africa), and Greenpoint NHLS Media Laboratory (Cape Town, 
South Africa)]  to exclude any discrepancies as the cation levels in the media could 
influence the aminoglycoside zone diameters (10). The aminoglycosides that will be 
tested by disc diffusion are gentamicin (10 µg), amikacin (30 µg), and tobramycin (10 
µg) [Oxoid, Basingstoke]. These antibiotics were chosen as they are used at local 
hospitals for treatment of acinetobacter infections. 
Isolated colonies from the single colony plate will be emulsified in normal saline to 
achieve an organism suspension with a density equivalent to 0.5 McFarland. The 
suspension will then be evenly applied onto the three different commercial Mueller-
Hinton media using a mechanical rotary device. The antibiotic discs are applied by 
tabbing them onto the agar using a disc dispensing device. Each plate must be checked 
to ensure that the discs are making complete contact with the agar as well as to ensure 
that they are >24 mm apart (centre-to-centre). The plates will be inverted and incubated 
within 15 minutes in an aerobic incubator at 35 ºC for 24 hours. 
After 24 hours, the susceptibilities will be determined using the methodology outlined in 
CLSI standards (See SOP 2, Part D). The diameters of the zone of inhibition will be 
measured to the nearest millimetre using a sliding calliper. The zone diameter will be 
interpreted using CLSI interpretative standards (4). The mean of the zone diameters 
obtained from all three media will be used in the analysis. 
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Epsilometric Tests (Etest) 
Introduction 
The Etest (AB Biodisk, Solna, Sweden) is a quantitative method for determining the 
antimicrobial susceptibility of a bacterial species. The system utilises a predefined 
antibiotic gradient which is used to determine the MIC (in µg/ml) of different antibiotics 
against organisms as tested on agar media using overnight incubation. The MIC 
generated is the minimal concentration of a drug, in µg/ml, which will inhibit the growth 
of a particular bacterium under defined experimental conditions. 
The Etest is a thin, inert, non-porous plastic strip that is 5 mm wide and 60 mm long. 
One side of the strip carries the MIC reading scale (in µg/ml) and a two letter code that 
represents the antibiotic being tested. A predefined exponential gradient of the antibiotic 
is present on the other surface of the strip. The gradient covers a continuous 
concentration range across 15 two-fold dilutions of a conventional MIC method. 
When an Etest is applied to the inoculated agar surface, there is immediate transfer of 
the antibiotic into the agar matrix. A stable, continuous and exponential gradient is 
formed under the strip. A symmetrical ellipse of inhibition becomes visible after the 
recommended incubation period. The Etest has been shown to be reproducible and 
equivalent to CLSI reference dilution methods. However, even under the best controlled 
conditions, a dilution test may not give the same end point each time it is performed. 
The reproducibility of the conventional dilution test is within +/- 1 two-fold dilution of the 
end point.  
 
Methodology 
MIC determination by Etest will be performed as per manufacturer’s instructions. Once 
again, a single Etest will be placed on three different commercially available Mueller-
Hinton agars to exclude the influence of variation of cation concentration on 
susceptibility testing. 
Individual bacterial colonies are homogenised in saline to 0.5 McFarland. A swab is then 
immersed into the suspension, excess fluid is removed, and the surface of the agar is 
swabbed evenly in three directions. The Etest will then be placed on the surface of the 
agar using a sterile forceps. Thereafter, the plate is placed into an aerobic incubator and 
incubated at 35 ºC for 24 hours (See SOP 3, Part D). 
The plates will be read only if sufficient growth is seen after the recommended 
incubation period. The MIC of an antibiotic is the point at which the ellipse intersects the 
scale. The end point is defined as complete inhibition of all growth including hazes and 
isolated colonies.  
CLSI interpretative standards will be utilized to interpret the MIC values obtained (4). 
Since the Etest is a continuous gradient, values in between two-fold dilutions may be 
obtained. These values will be rounded up to the next two-fold dilution before 
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interpretation. The Etest results will be compared to the reference broth microdilution 
results, and the results obtained from the medium which most closely agrees with the 
results from the reference method will be used for analysis purposes. 
 
Vitek®2 Susceptibility Testing  
Introduction 
The Vitek®2 system is an automated susceptibility test method that utilises plastic 
reagent cards containing antibiotics in a 64-well format. The system employs repetitive 
turbimetric monitoring of bacterial growth during an abbreviated incubation period of 4-
10 hrs. Using a unique algorithm, an MIC is calculated. The Vitek®2 uses an “expert 
system” computer software programme to interpret susceptibility results and analyses 
the results for atypical patterns or unusual resistance phenotypes.  
 
Methodology 
Susceptibility testing will be performed using the same standard operating procedure as 
for Vitek®2 identification. A Vitek®2 Gram Negative Susceptibility card (NO-22) will be 
used to determine the susceptibility of each isolate at 0.6 McFarland and 1.0 McFarland, 
respectively.  
 
The concentrations of the aminoglycoside antibiotics in the card are as indicated in 
Table 2.   
 TABLE 2: Concentrations of antibiotics in NO-22 card.                
Antibiotic      Code  Concentration Calling Range 
Amikacin AN 8, 16, 64 ≤ 2; ≥ 64 
Gentamicin GM 4, 16, 32 ≤ 1; ≥ 16 
Tobramycin TM 8, 16, 64 ≤ 1; ≥ 16 
Netilmicin NET 4, 16, 32 ≤ 1; ≥ 32 
 
Table obtained from AST NO-22 Card, Package Insert, bioMérieux, 2006. 
 
Agar dilution 
Agar dilution, the second reference method, is a truncated method that incorporates one 
or two selected concentrations of antimicrobials, usually at breakpoint values (10, 22). 
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This technique involves the incorporation of different concentrations of the antimicrobial 
substance into a nutrient agar medium followed by the application of a standardised 
inoculum of bacteria to the surface of the agar plate. The plates are then incubated at 
35 ºC for 18 hrs. Sensitive organisms are inhibited by the concentration of antibiotic in 
the agar, and no growth is evident at the points of inoculation. Resistant organisms 
appear as distinct colonies of bacterial growth (23).  
The agar dilution method will be performed by the Research and Development Division 
of bioMérieux in LaBalme, France. The methodology used for testing will follow CLSI 
standards. Only tobramycin susceptibility will be performed for all isolates as tobramycin 
is the antibiotic that we have experienced the most problems with. The agar dilution 
technique will be performed in duplicate by two independent technologists. The results 
obtained will be compared to the reference method, and the lab worker whose results 
most closely match the results of reference method will be used for analysis. 
 
Broth microdilution 
The broth microdilution test serves as the reference method for susceptibility testing. 
Serial dilutions of antimicrobial agent to be tested are added to broth in a 96 well plate. 
A standardized bacterial suspension is then added. Growth is assessed after incubation 
for a defined period of time (16–20 h). At the end of the incubation period, the wells are 
visually inspected. Cloudiness indicates that the bacterial growth has not been inhibited 
by the concentration of antibiotic in the well, whereas a clear well indicates that the 
bacteria have been inhibited by the concentration of antibiotic in the well (23).  
The broth microdilution will be performed by the Research and Development Division of 
bioMérieux in LaBalme, France, due to lack of local resources and expertise. Testing 
will follow CLSI standards. The broth microdilution will be performed on three 
aminoglycoside antibiotics, i.e. gentamicin, amikacin, and tobramycin. The method will 
be performed in duplicate by two technologists working independently. CLSI 
interpretative criteria will be utilized for interpretation of the MIC values obtained (4). 
Discrepant results will be reconciled by choosing the result with the higher MIC value. 
This accords with standard laboratory practice as theoretically these results would be 
used to influence choice of antibiotic in critically ill patients. 
 
Quality control 
To ensure standardization of results, all susceptibility testing performed in Cape Town 
will be performed by a single investigator working under standardised conditions using 
standard operating procedures in a SANAS accredited laboratory. The investigator will 
be observed by two independent observers (from bioMérieux) to ensure that no 
deviation from the standard operating procedures occurs.  
Quality control procedures as outlined in CLSI guidelines as well as the Vitek®2 
manufacturer’s guidelines will be followed (3, 4). Quality control using the recommended 
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American Type Culture Collection (ATCC) organisms will be performed for each lot 
number of media, antibiotic discs, Etests, and Vitek®2 cards utilised in the study.  
 
MOLECULAR TESTING 
 
DETECTION OF MECHANISM OF RESISTANCE 
The mechanisms of aminoglycoside resistance amongst A. baumannii isolated at the 
clinical diagnostic laboratory have previously been researched by the Division of 
Medical Microbiology, University of Cape Town (8). The prevalent mechanism of 
resistance to tobramycin was an aminoglycoside modifying enzyme encoded by the 
aac(3)-IIa gene (8). 
Based on this observation, a PCR will be performed on all isolates to confirm the 
presence or absence of the aac(3)-IIa gene.  
 
Methodology 
The NucliSens® easyMag® platform (bioMérieux, Durham, North Carolina) will be used 
for DNA extraction. This is an automated system for extraction of nucleic acids based 
upon silica extraction technology. The samples are incubated with lysis buffer overnight. 
The target nucleic acids are captured by silica particles. The NucliSens® easyMag® 
magnetic device attracts all the magnetic silica, enabling the system to purify the nucleic 
acids through several wash steps. The heating step releases the nucleic acids from the 
silica, and the magnetic beads are then separated from the eluate by the magnetic 
device. 
The quantity and quality of DNA extracted will be confirmed using the Nanodrop® ND-
1000 spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA). 
The PCR assay utilised has been optimised and validated by previous work performed 
by medical scientists at the Institute of Infectious Diseases and Molecular Medicine, 
University of Cape Town (8). The sequences of the primers that will be used are shown 
in Appendix 1. 
The mastermix consists of magnesium chloride(25 mM), 2.5 mM of each dNTP, forward 
and reverse primers (20 pmoles each), and 2.5U Taq polymerase in buffer made up to a 
final volume of 50 µL per reaction (8). Genomic DNA (8-80 ng/µL) will be added to the 
mastermix. The mixture will be placed in a thermocycler using the following cycling 
conditions: an initial denaturation at 95 °C for 5 minutes, followed by 35 cycles of 95 °C 
for 1 minute, 51 °C for 45 seconds, 72 °C for 1 minute, and a final extension at 72 °C for  
5 minutes (9). MOS-1, a known Acinetobacter baumannii strain with the aac(3-)IIa gene 
will be used as a positive control, while MOS-2 will be used as a negative control (8).  
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The PCR product will be separated in an agarose gel and visualised by 
transillumination. The expected product size is 786 bp (8). The assay will be repeated 
on all samples with an initial negative result. To confirm the integrity of DNA extracted, a 
16s rRNA PCR will also be performed on all isolates (See SOP 5, Part D). 
Selected isolates will be sequenced by the DNA sequencing facility at the University of 
Stellenbosch, South Africa. The DNA sequences will be analysed using Chromas Lite 
v2.01 (Technelysium Pty Ltd) and BioEdit Version 7.0.9 software. The sequences will be 
blasted on Genbank for nucleic acid similarity with existing sequences. 
 
Quality control 
The molecular tests will be performed in designated molecular areas within a SANAS 
accredited laboratory. Positive and negative controls will be included for all stages of 
molecular testing. Standard operating procedures will be strictly adhered to. 
 
EPIDEMIOLOGY OF ISOLATES 
 
REP-PCR 
The isolates will be typed by rep-PCR using the Diversilab System by the bioMérieux 
Research and Development team in France. This will be performed to determine if there 
is a predominant clone that is responsible for the disparity in tobramycin susceptibility 
testing. The Diversilab System is an automated DNA fingerprinting and analysis tool 
based on rep-PCR technology. The technique consists of three parts: isolation of DNA 
from bacteria with a Diversilab™ Acinetobacter kit, amplification of the isolated DNA 
using rep-PCR, and detection of the amplified material by electrophoresis. Rep-PCR 
primers bind to many specific repetitive sequences interspersed throughout the bacterial 
genome. Multiple fragments of differing lengths are amplified. These fragments are then 
separated by mass and charge via electrophoresis. A unique fingerprint is created with 
multiple bands of varying intensity. Software analysis of the fingerprints generated may 
be used to create dendrograms, scatterplots, etc. This will then be used to evaluate the 
degree of similarity between the isolates utilised in this study. See Part D for detailed 
methodology. 
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Pulsed field gel electrophoresis (PFGE) 
 
Introduction 
PFGE is considered the gold standard for typing of A. baumannii (18, 19). This 
technique has the highest discriminatory power, and interlaboratory reproducibility is 
possible through the use of standardised protocols (18, 19). PFGE will be performed to 
further investigate the relatedness of A. baumannii strains included in this study to a 
previously characterised tobramycin resistant strain isolated at Groote Schuur Hospital. 
The methodology for the PFGE has already been optimized by medical scientists at the 
Institute of Infectious Diseases and Molecular Medicine, University of Cape Town (8).  
 
Methodology 
Briefly, agarose plugs containing a bacterial suspension and sodium dodecyl sulphate 
(C12H25NaO4S), to lyse the bacteria, will be prepared. After lysis, the plugs will be 
washed and the DNA will be digested with Apa1 (Roche). Following digestion, the plugs 
will be loaded into an agarose gel in preparation for electrophoresis. The 
electrophoresis will be carried out in a Gene Navigator® PFGE machine (Amersham 
Biosciences AB, Uppsala, Sweden) for 23 hours, after which it will be stained with 
ethidium bromide, destained, and photographed (See SOP 7, Part D). The patterns will 
be visually inspected and interpreted using Tenover criteria (20). An analysis using 
GelCompare II Version 4.6 (Applied Maths, Sint-Martens-Latem, Belgium) software will 
be used to further analyse the profiles obtained (7). 
 
DISCUSSION AND IMPACT 
This study has been proposed to inform the diagnostic laboratory on whether the 
Vitek®2 automated system is an accurate means of testing for tobramycin susceptibility 
in A. baumannii.  In addition, an assessment of the accuracy of the various methods in 
determining sensitivity is critical as inappropriate antimicrobial therapy is associated with 
increased morbidity and mortality. 
 
ENVISAGED OUTCOMES 
The results of this study may lead to changes in standard operating procedure with 
respect to aminoglycoside susceptibility testing at Groote Schuur Hospital, as well as 
other NHLS laboratories in South Africa. In addition, a revision of the product or 
package insert may have to be made by the manufacturer. 
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This study will form the basis of research toward a MMed dissertation. The findings of 
this project are expected to be published in an international peer reviewed journal, and 
the data is expected to be presented at an international microbiology congress either as 
an oral presentation or as a poster submission. 
 
ETHICAL CONSIDERATIONS 
Ethical approval was sought from the University of Cape Town Human Research Ethics 
Committee (REF REC 458/2006). See Appendix 1, Part D. 
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APPENDIX 1: 
 
Sequence of aac(3)-IIa gene which encodes the AAC(3)-IIa enzyme. 
                        
ATGCATACGCGGAAGGCAATAACGGAGGCAATTCGAAAACTCGGAGTCCAAACCGGTGACCTGTTGATGGTGCA
TGCCTCACTTAAAGCGATTGGTCCGGTCGAAGGAGGAGCGGAGACGGTCGTTGCCGCGTTACGCTCCGCGGTTGG
GCCGACTGGCACTGTGATGGATACGCGTCGTGGGACCGATCACCCTAACGAGGAGACTCTGAATGGCGCTCGGTT
GGATGACAAAGCCCGCCGTACCTGGCCGCCGTTCGATCCCGCAACGGCCGGGACTTACCGTGGGTTCGGCCTGCT
GAATCAATTTCTGGTTCAAGCCCCCGGCGCGCGGCGCAGCGCGCACCCCGATGCATCGATGTCGCGGTTGGTCCG
CTAGCTGAAACGCTGACGGAGCCTCACGAACTCGGTCACGCCTTGGGGAAAGGGTCGCCCGTCGAGCGGTTCGTC
CGCCTTGGCGGGAAGGCCCTGCTGTTGGGTGCGCCGCTAAACTCCGTTACCGCATTGCACTACGCCGAGGCGGTT
GCGGATATCCCCAACAAACGATGGGTGACGTATGAGATGCCGATGCTTGGAAGAAACGGTGAAGTCCGCCTGGA
AAACGGCATCAGAATACGATTCAAACGGCATTCTCGATTGCTTTGCTATCGAAGGAAAGCCGGATGCGGTCGAAA
CTATAGCAAATGCTTACGTGAAGCTCGGTCGCCATCGAGAAGGTGTCGTGGGCTTTGCTCAGTGCTACCTGTTCGA
CGCGCAGGACATCGTGACGTTCGGCGTCACCTATCTTGAGAAGCACTTCGGAGCCACTCCGATCGTGCCAGCACAC
GAAGCCGCCCAGCGCTCTTGGCGAGCCTTCCGGTTA 
 
The start and stop codon for the aac(3)-IIa gene are indicated in bold type. The forward primer is 
indicated in green and the reverse primer is indicated in blue. The arrows indicate the direction of 
transcription.  
  
(Adapted from: Jacobson, R. K. 2007. M. Sc thesis. Association of IS1133 with an aminoglycoside 
resistance gene,  aacC2a, in Acinetobacter baumannii isolates. University of Cape Town). 
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LITERATURE REVIEW 
Acinetobacter baumannii has emerged as a major nosocomial pathogen world-wide (1, 
20, 21, 115, 124). The organism has gained increased notoriety with its classification as 
a high priority pathogen by the Antimicrobial Availability Task Force of the Infectious 
Diseases Society of America (109). This bacterium presents several problems to the 
microbiologist and clinician. A. baumannii has the capacity for long-term survival in the 
hospital environment, rapidly filling the ecological niche left vacant by the elimination of 
competing bacteria by broad-spectrum antibiotics (111). Infections due to A. baumannii 
are associated with increased morbidity and mortality in critically ill patients in ICUs. 
Genetic interchange with other bacterial species is possible with significant implications 
for the rapid acquisition of resistance determinants, and subsequent spread of multi-
drug resistant strains (82). Considerable information has been obtained about the 
mechanisms of antibiotic resistance, but we are only beginning to understand the 
virulence factors and pathogenicity potential of this complex bacterium. 
  
1. MICROBIOLOGY    
1.1 TAXONOMY OF ACINETOBACTER 
The taxonomy of Acinetobacter spp. has a convoluted history. The organism was first 
described in 1911 by the Dutch microbiologist, Beijerinck, who isolated the organism 
from the soil in a calcium-acetate-containing minimal medium (82, 111). In 1954, Brisou 
and Prevot proposed the current genus designation to separate the non-motile from the 
motile organisms within the genus Achromobacter (82). This designation was accepted 
in 1968. In 1991, Acinetobacter spp. were designated as belonging to the family 
Moraxacellaceae, within the γ-subclass of the Proteobacteria (94). 
Acinetobacter was initially classified as a single species genus in 1968, but at present 
there are 33 species (111). Twenty-three of these have been named; the remaining 10 
are classed as genomic species. Genospecies 1(Acinetobacter calcoaceticus), 
genospecies 2 (A. baumannii), genospecies 3, and genospecies 13 compose the A. 
calcoaceticus- A. baumannii complex. These four species are closely related 
genotypically, and are phenotypically very difficult to distinguish. The difficulty of 
accurate speciation has created problems in establishing the epidemiology and true 
clinical importance of A. baumannii. However, accurate speciation is important as 
clinical significance and antimicrobial susceptibility varies between species (111). In 
addition, the epidemiology and propensity for spread is also species dependent.  
Species identification is, however, often difficult for both clinical diagnostic and research 
purposes. Whilst the majority of acinetobacters are environmental organisms which are 
not associated with human disease, A. baumannii has emerged as a successful 
pathogen in the 21st century. 
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1.2 NATURAL HABITATS 
Acinetobacter spp. are ubiquitous organisms. They have been isolated from numerous 
sites, including the soil and water, from which A. calcoaceticus, and Acinetobacter 
johnsonii are common isolates (26, 111). Acinetobacter have been found colonising 
animals (including arthropods) and have even been isolated from food (9, 60). 
Acinetobacter  lwoffii, Acinetobacter radioresistens  and A. johnsonii are commonly 
found colonising human skin (111). In addition to colonising skin, A. baumannii  has the 
ability to colonise indwelling devices including urinary catheters, neurosurgical shunts, 
and central venous lines (26, 111). In the hospital environment, A. baumannii are 
usually associated with moist environments such as ventilators, humidifiers, and sinks. 
The natural habitat of A. baumannii outside the hospital, however, is yet to be 
determined (111). 
Recovery of acinetobacter from various clinical specimens, for example sputum, urine, 
or faeces, can represent colonization of the body site, contamination when obtaining the 
specimen through a colonised opening, or true infection of the site. 
 
1.3 SPECIES IDENTIFICATION 
Acinetobacter spp. are short gram-negative bacilli, often appearing cocco-bacillary on 
Gram stain (122).They may appear gram-positive when stains are made directly from 
blood culture bottles (122). 
Acinetobacter may be cultivated on several types of media commonly utilised in the 
diagnostic laboratory. A. baumannii is saccharolytic, and may therefore appear as a 
lactose-fermenter on MacConkey agar (122). The colonies are approximately 0.5-
2.0mm in diameter, domed, mucoid, and non-pigmented (122). 
The identification of acinetobacter to genus level depends on the following phenotypic 
traits: a strictly aerobic, non-motile, non spore-forming, non-fermenting gram-negative 
bacillus, which is catalase-positive, oxidase-negative, with a G+C content of 39 to 47% 
(82, 122). A. baumannii has the following differentiating phenotypic reactions from other 
non-fermenting gram-negative bacilli: It is saccharolytic (utilises glucose, lactose, and 
xylose, but not maltose), non-haemolytic, and grows at 42ºC (12, 57). Special 
chromogenic medium is available for rapid identification of A. baumannii within 24 hours 
(43). 
Several automated and semi-automated identification tests have been developed for 
commercial use. These include the API20E, Vitek2, MicroScan WalkAway, and BD 
Phoenix. These tests have made identification of bacterial species much easier, quicker 
and more cost-efficient. However, they have been shown to have a limited database, 
and tend to group A. baumannii, genomic group 3 and genomic group 13TU into one 
group, identified as Acinetobacter baumannii (26, 82). 
The problems associated with phenotypic testing led to the development of other tests 
for identification. The DNA transformation assay of Juni utilises the ability of a strain to 
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transform Acinetobacter strain BD413 trypE27, a tryptophan auxotroph, to a wild-type 
phenotype, as a pre-requisite to belong to the genus Acinetobacter (52). Molecular tests 
include16s rDNA sequence analysis, DNA-DNA hybridization, protein SDS PAGE 
fingerprinting, amplified fragment length polymorphism (AFLP) fingerprinting, amplified 
rDNA restriction analysis (ARDRA), and ribotyping (26, 40, 82). Although they are more 
accurate, they are laborious, require considerable skill and, therefore tend to be 
restricted to reference or research laboratories. 
2. PATHOGENESIS AND VIRULENCE FACTORS 
Acinetobacter first began to be recognized as a nosocomial pathogen in the 1970s. 
Today, A. baumannii accounts for 2-10% of gram-negative bacterial infections in 
Europe, and 2.5% of these infections in the United States (45, 50). 
 
2.1 INFECTIONS 
A. baumannii was previously thought to be a low virulence organism causing infections 
in predominantly immunocompromised and debilitated patients, but this view is 
changing. This organism is capable of causing a spectrum of diseases. 
Acinetobacter has been implicated in clinical infections in immunosuppressed and 
critically ill patients in intensive care units worldwide, particularly patients requiring 
mechanical ventilation, and those with wounds or burn injuries (111). It has also been 
implicated in community-acquired infections (32, 49, 75). A. baumannii was identified as 
a significant cause of skin and soft-tissue infections in US soldiers during the wars in 
Iraq and Afghanistan (16). Following the tsunami in South-East Asia in December 2004, 
17% of 17 people evacuated to Germany with severe trauma had multidrug-resistant A. 
baumannii  isolated from wound swabs, sputum and blood cultures (65). 
This organism has been implicated in several types of nosocomial infections. In the 
Surveillance and Control of Pathogens of Epidemiologic Importance (SCOPE) study 
conducted in the US in 1995-2002, acinetobacter ranked as the 10th leading cause of 
bloodstream infections (0.6 bloodstream infections per 10,000 admissions) (123). In the 
same study, acinetobacter had the third highest crude mortality rate (34%) in ICU 
patients after Pseudomonas(39.2%) and Candida species infections(38.7%) (123). 
This organism is frequently isolated from patients with ventilator-associated pneumonia, 
and is associated with a high mortality rate. Acinetobacter spp. ranked fourth (6.9%) in 
prevalence amongst gram-negatives causing pneumonia in ICUs as reported to the 
National Nosocomial Infection Surveillance system in 2003 (39). 
Acinetobacter has also been implicated in secondary meningitis; ventriculitis; urinary 
tract infections; surgical site infections; chronic ambulatory peritoneal dialysis related-
peritonitis, and even endocarditis (10, 14, 48, 54, 73, 80, 82, 91). 
Risk factors for nosocomial infection include host factors  such as a high APACHE II 
score, prematurity, malignancy and length of hospitalization (26, 74). Prior antimicrobial 
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therapy (the use of cephalosporins, carbapenems, and quinolones) are additional risk 
factors for acquisition of nosocomial infection particularly with multidrug-resistant 
phenotypes (74). The type of medical intervention e.g. surgery, catheterisation, or  
mechanical ventilation, as well as environmental factors such as insufficient adherence 
to infection control guidelines by healthcare workers, also plays a role in acquisition of 
infection. 
Risk factors for community-acquired infection include chronic obstructive airways 
disease, renal failure, diabetes mellitus, smoking and alcohol abuse (26, 32). 
Community-acquired pneumonia caused by A. baumannii is associated with a with an 
acute onset of respiratory failure and shock, and a high mortality rate (40-64%) (18, 32). 
2.2 VIRULENCE FACTORS 
The organism possesses several factors that may contribute to its pathogenicity. These 
include fimbriae or pili for attachment to cell structures, outer membra e proteins (that 
may function as a resistance mechanism), and lipopolysaccharide (19, 42). Outer 
membrane protein A (OmpA) is thought to be responsible for inducing apoptosis in the 
cells that the bacterium invades (19). In addition, acinetobacter is capable of capsule 
and biofilm production. In one study, more than 60% of A. baumannii from clinical 
isolates formed biofilm (93). This allows acinetobacter to produce infections associated 
with indwelling devices, such as urinary and intravenous catheters. Biofilms contribute 
to drug resistance and provide a means for acinetobacter to evade the immune 
defences. Further, exopolysaccharide from biofilms has been shown to suppress 
neutrophil activity and contribute to serum resistance (42).  
Siderophores for iron acquisition, which is essential for bacterial growth, have been 
found in acinetobacter (126). Several extracellular enzymes are known to be produced 
by this bacterium. These include proteases, gelatinases, esterases, leucine arylamidase 
and phospholipases (17). A Type IV secretion system and quorum sensing machinery 
have also been detected among the organism’s armamentarium (113). 
Lipopolysaccharide from the bacterium has been shown to be a potent inducer of the 
pro-inflammatory cytokine cascade in human monocytes, via Toll-like receptor (TLR)-2 
and TLR-4 pathways (30). Acinetobacter is capable of uptake of DNA released by other 
bacteria in its environment. This transformation may result in the acquisition of drug 
resistance genes and pathogenicity islands. In addition, some strains of A. baumannii 
have been shown to be resistant to serum killing by complement (55). 
 
3. EPIDEMIOLOGY OF ACINETOBACTER BAUMANNII 
The incidence of acinetobacter infections has been increasing, both locally and 
worldwide. Several outbreaks have been reported in the literature. These have been 
reported in England, France, Portugal, Spain, Australia, Asia, the US and South Africa 
(21, 22, 24, 46, 69, 70, 77, 82, 115, 116). Eight worldwide clonal lineages that are 
associated with epidemic spread throughout the world have been described (46). 
Strains belonging to European Clone I and II have been implicated in outbreaks since 
the 1980s (26, 79). A study on the dissemination of the southeast (SE) clone of A. 
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baumannii  containing OXA-23 has revealed that it was the cause of outbreaks in 
several ICU’s in the United Kingdom resulting in closures (22). This clone is usually 
susceptible only to tigecycline and the polymyxins (64).  
  
Acinetobacter may be transmitted from patient to patient through the hands of 
healthcare workers, and possibly by airborne transmission (26, 111). Colonized patients 
are thus the primary reservoir for acinetobacter in the hospital environment. Other 
possible sources are contamination of surfaces close to the patient or medical 
equipment (e.g. ventilators) (15, 41). Acinetobacter has been shown to survive on dry 
surfaces from 3 days up to 5 months (56). The simplicity of this organism’s nutritional 
requirements combined with its ability to survive at different temperatures and pH 
values, explains its remarkable ability to thrive in a variety of environments (56). 
Most nosocomial outbreaks are usually related to a single hospital ward, such as the 
ICU, and caused by a single or a few clones with a common environmental source 
usually implicated. These outbreaks are usually resolved once the reservoir is identified 
and eliminated. Infection control measures to inhibit A. baumannii transmission include 
the use of closed tracheal suction, improved hand decontamination using alcohol gels, 
strategies to clean equipment and the environment, and the use of nebulised colistin for 
patients with mild-moderate VAP (33, 92, 112).  
Several methods have been developed to determine the genetic relatedness of       A. 
baumannii implicated in outbreaks. These include phenotypic testing such as biotyping, 
resistance phenotyping, serotyping, and phage typing (8). The problems with these 
methods are that they are not discriminatory enough, and up to 20% of bacteria are not 
typable by phage typing.  DNA-based epidemiologic tools (Table 1) include plasmid 
profile analysis, ribotyping, random amplified polymorphic DNA (RAPD), repetitive 
extragenic polymerase chain reaction (REP-PCR), amplified fragment length 
polymorphism (AFLP), integrase gene PCR, multilocus sequence typing (MLST), 
electrospray ionisation mass spectrometry(ESI-MS), and pulsed-field gel 
electrophoresis (11, 28, 82, 101-103, 105, 114). It should be noted that many of these 
techniques are no longer in the domain of a research laboratory. 
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TABLE 1: Molecular techniques for epidemiological studies. 
Technique Advantages Disadvantages 
Plasmid profile analysis Nil. Plasmids may be lost/ gained. 
Cumbersome technique. 
Ribotyping Automated systems available. Labour intensive, poor 
discriminatory power. 
PFGE Gold standard, highest 
discriminatory power. 
Labour intensive. 
RAPD-PCR Easy, rapid, low cost. Reproducibility poor; 
discrimination inferior to 
PFGE. 
AFLP High discriminatory power, 
robust. 
Expensive, requires 
experienced technologist. 
 
MLST Reproducible, portable. Expensive, time consuming. 
ESI-MS Rapid, high-throughput, easy. Expensive, not for routine use. 
 
 
4. TREATMENT OF ACINETOBACTER INFECTIONS 
The treatment of acinetobacter infections has become increasingly difficult as 
therapeutic options diminish. This has prompted the use of off-label drugs, such as 
colistin. 
Antibiotics that are utilised for the treatment of acinetobacter infections include the anti-
pseudomonal penicillins, the anti-pseudomonal cephalosporins, sulbactam, 
monobactams, aminoglycosides, tetracyclines, quinolones, trimethoprim-sulphonamide, 
and the carbapenems. Options available for drug resistant isolates include the 
polymixin, colistin, and the glycylcycline, tigecycline (37). Clinical trials of the use of 
combination therapy, such as colistin and rifampicin, or a carbapenem and an 
aminoglycoside, for the treatment of MDR acinetobacter infections have yielded 
somewhat mixed results (53). However, there are numerous case reports of successful 
treatment of patients with MDR acinetobacter infections with these combination 
therapies (6, 37). Aminoglycosides in combination with meropenem or polymixin B are 
recommended for empirical treatment of acinetobacter meningitis (54). Novel agents 
such as antimicrobial peptides, enzyme inhibitors, and efflux pump inhibitors are 
currently under investigation for the treatment of pan drug-resistant isolates. 
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The administration of an appropriate antibiotic in treating sepsis is a strong predictor of 
mortality (29, 38, 47, 59). In most cases, antibiotic therapy is initiated prior to 
identification of the causative organism. Empirical therapy is often inappropriate when 
treating MDR acinetobacter infections, thus leading to an unfavourable outcome. In a 
study in Turkey where 51% of the acinetobacters isolated from bloodstream infections 
were resistant to imipenem, only 14 of 41 patients with A. baumannii bacteraemia 
received appropriate antimicrobial therapy (4). A Canadian study involving 14 ICUs 
documented that  the administration of an appropriate antibiotic in the 1st hour of 
hypotension was associated with a survival rate of 79.9% (59). However, each hour of 
delay in administration of an antibiotic over the next 6 hours was associated with a 7.6% 
decrease in survival (59). In a study conducted in Turkey, inappropriate empirical 
antibiotic therapy in acinetobacter sepsis was associated with a 65% mortality versus 
39.5% for patients who received appropriate therapy (29). Another study in Thailand 
showed that patients with a pan drug- resistant acinetobacter infection had an 80% 
mortality versus 14% of controls infected with a drug-sensitive acinetobacter (5). 
Interestingly, only 75 % (42/56) of these patients received appropriate empirical therapy 
(5). However, the literature is conflicting as some studies have found a poor correlation 
between patient mortality and inappropriate empirical antibiotic choice (23, 72). The lack 
of consensus on the contribution of acinetobacter to patient mortality may be due to 
multiple confounders in these studies. These include study population, study design, the 
distinction between infection and colonisation in critically ill patients, and lack of 
information about virulence factors (31). Although the evidence for the impact on 
mortality has not been established, several studies have shown an increase in patient 
hospital stay, a requirement for mechanical ventilation and increased treatment costs 
(31). In general, the outcome for patients infected and colonised with A. baumannii 
seems to be poor. 
5. MECHANISMS OF ANTIBIOTIC RESISTANCE 
In 1946, Alexander Fleming stated, “There is probably no chemotherapeutic drug to 
which in suitable circumstances, the bacteria cannot react by in some way acquiring 
‘fastness’ (resistance)” (3). This statement still holds true today, particularly with 
reference to A. baumannii. This organism was susceptible to most antibiotics in the 
1970s, but has now acquired a remarkable propensity to rapidly gain resistance to most 
antibiotics (111). 
Susceptibility studies carried out in the early 1970s revealed that acinetobacter was 
susceptible to most commonly used antimicrobials, including ampicillin (60-70% 
isolates), gentamicin (92.5%), chloramphenicol (57%), and nalidixic  acid (97.8%) (7). 
Thirty years later, A. baumannii has emerged as a multidrug resistant organism. 
Antibiotic resistance in A. baumannii is diverse, and includes target gene mutation, 
enzymatic modification of the antibiotic, altered membrane permeability, and 
unregulated efflux pump activity (Figure 1). The efflux systems involve protein 
transporters that function to reduce the concentration of an antibiotic by transporting 
them across the bacterial cell membrane into the external environment. 
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FIGURE 1: Diagram of the cell wall of A. baumannii. 
Adapted from: Munoz-Price, LS, Weinstein, RA. Acinetobacter Infection. NEJM. 2008; 358: 1271-1281. 
 
In a survey by the Centers for Disease Control (CDC) involving 300 hospitals in the US, 
carbapenem resistance in A. baumannii increased from 9% in 1995 to 40% in 2004 (75). 
In the UK, resistance to carbapenems rose from <0.5% in the 1990s to 24% in 2007 
(111). Statistics from South Africa revealed that at Groote Schuur Hospital, carbapenem 
resistance increased from 43-45% in 2006 to 75-78% in 2008 for A. baumannii isolates 
cultured from blood (unpublished, National Antibiotic Surveillance Forum, NHLS public 
sector susceptibility data, personal communication with Dr Colleen Bamford). 
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5.1 INTRINSIC RESISTANCE 
Acinetobacter has a cell membrane that is significantly less permeable than other Gram-
negative bacteria. Sato and Nakae demonstrated that the permeability co-efficients of 
zwitterionic cephalosporins in the intact cell outer membrane of A. calcoaceticus  was 
two to seven times lower than the permeability coefficients of Pseudomonas aeruginosa 
(97). They also demonstrated that the diffusion rates of carbapenems and zwitterionic 
cephalosporins appeared to be 1-3% that of Escherichia coli  membrane (97). These 
authors postulated that this was due to the small number of small-sized porins in the 
acinetobacter cell membrane (97). 
Other mechanisms of intrinsic resistance include outer membrane proteins, such as loss 
of CarO which is associated with carbapenem resistance, and the intrinsic production of 
oxacillinase, OXA-51 (76). 
 
5.2 ACQUIRED RESISTANCE 
The most common mechanism to explain the rapid gain in resistance of A. baumannii is 
the acquisition of plasmids, transposons and integrons, which carry clusters of 
resistance genes resulting in simultaneous resistance to several antibacterials (3). 
Large genomic islands containing multiple antibiotic resistance genes have been 
identified in acinetobacter; for example, A. baumannii AYE, a strain epidemic in France, 
contains a 86kb resistance island comprising 45 resistance genes inserted in its 
chromosome (34). Some genes isolated in this resistance island mediate resistance to 
beta-lactams, streptomycin, aminoglycosides, trimethoprim-sulphonamide, 
chloramphenicol, tetracyclines, and rifampicin (34). A recent study revealed that MDR A. 
baumannii can possess at least eight resistance determinants that give rise to its MDR 
phenotype (68). 
 
5.2.1 β-LACTAMS 
Resistance to the penicillins is mediated by chromosomal beta-lactamases          
(ampC). Cephalosporin resistance may be mediated by ampC overexpression through 
introduction of the insertion sequence ISAba1 upstream of blaAmpC, oxacillinases, 
changes in penicillin binding proteins (PBPs), porin loss and efflux pumps (82, 85, 95, 
100). Extended spectrum beta-lactamases (ESBLs) such as PER-1, PER-2, VEB, and 
CTX-M, have also been isolated in A. baumannii (81, 83, 86). Carbapenemases which 
afford protection against the broad-spectrum carbapenems are also part of A. 
baumannii’s armamentarium. OXA-23, an oxacillinase with carbapenemase activity, has 
now been identified in more than 50 different centres in the UK (Table 2) (63). Other 
carbapenemases isolated from A.baumannii include OXA-24, OXA-58, and IMP/VIM 
(85). The expression of these carbapenemases are dependent on promoter sequences 
within the insertion sequence, ISaba1 (98). 
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TABLE 2: Oxacillinases isolated from A. baumannii. 
Enzyme Geographical 
Distribution 
Location  Associated IS elements 
OXA-23 Cluster Europe, 
Australia,China, 
Korea, United 
States, Vietnam, 
Brazil, Pakistan 
Plasmid or 
chromosomal 
ISAba1, ISAba4 
OXA-24 Cluster Spain, Belgium, 
France, Portugal, 
United States 
Chromosomal or 
plasmid 
None. 
OXA-58 Cluster France, Spain, 
UK, Australia, 
Italy, United 
States, Greece 
Pakistan, 
Romania 
Plasmid or 
chromosomal 
ISAba1, ISAba2, ISAba3, IS 
18 
OXA-51 Cluster Naturally 
occurring, 
therefore found 
worldwide. 
Chromosomal ISAba1 
Adapted from: Peleg AY, Seifert, H, Paterson, DL.  Acinetobacter baumannii: Emergence of a Successful 
Pathogen. Clinical Microbiology Reviews. 2008 (July); 21(3): 538-582. 
 
Oxacillinase-23, OXA-64 and OXA-71 have been isolated from A. baumannii strains 
from South Africa (84, 99). 
Resistance to carbapenems may also be mediated by other mechanisms such as porin 
losses or modifications, changes in outer membrane proteins, or rarely changes in 
PBPs (25, 87). 
 
5.2.2 QUINOLONES 
Quinolone resistance is mediated mainly by mutations in GyrA and/or ParC which result 
in alteration of the antibiotic target, the topoisomerases (44, 117, 118). Efflux pumps 
and porin losses are additional mechanisms that A. baumannii employs to defend itself 
against the quinolones. The AdeM efflux pump, a member of the MATE family, confers 
resistance to norfloxacin, ofloxacin, and ciprofloxacin (107). 
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5.2.3 TETRACYCLINES AND GLYCYLCYCLINES 
Tetracycline resistance is mediated through several efflux pumps. These include TetA, 
TetB, TetC, TetD and TetE which afford resistance to the tetracyclines and CmIA which 
affords resistance to chloramphenicol (3, 89). These efflux pumps are part of the major 
facilitator superfamily (MFS) group. The AdeABC efflux pump, which is a member of the 
Resistance Nodulation Division (RND) group, confers resistance to the tetracyclines, 
chloramphenicol, β-lactams, aminoglycosides, erythromycin, and reduced susceptibility 
to fluoroquinolones (96). Ribosomal protection by proteins TetM and TetO are another 
resistance mechanism to tetracyclines (90). 
Although tigecycline has only been recently introduced as a novel antibiotic, resistance 
to it has been documented amongst A. baumannii strains (78, 88). The major 
mechanism of resistance is an efflux pump, the AdeABC efflux pump (96). 
 
5.2.4 POLYMIXINS 
Postulated mechanisms of resistance to colistin include mutations that modify the 
lipopolysaccharide that make the cell membrane more resistant to the detergent action 
of this group of antibiotics, proteolytic cleavage of the drug, and activation of a broad-
spectrum efflux pump (37). 
 
5.2.5 AMINOGLYCOSIDES 
The aminoglycoside group of antibiotics include gentamicin, amikacin, tobramycin 
(Figure 2), netilmicin, kanamycin and streptomycin. These antibiotics are hydrophilic 
molecules, consisting of a central aminocyclitol ring linked to one or more amino sugars 
by pseudoglycosidic bond(s) (66). This group of antibiotics bind specifically to 16S RNA 
in the 30S ribosomal subunit of the bacterium and inhibit protein    synthesis (66). This 
results in mistranslated proteins that have a fatal secondary effect on the bacterium 
(66). 
 
                                
FIGURE 2: Chemical structure of tobramycin sulphate.  
Downloaded from:  www.chemicalbook,com/ChemicalPropertyProduct_EN_CB6678801.htm. 
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The aminoglycosides have been used as monotherapy or in combination with other 
antibiotics for the treatment of acinetobacter infections. Many MDR A. baumannii retain 
susceptibility to amikacin or tobramycin. In a global survey (2001-2004), 60% of 
Acinetobacter spp. remained susceptible to amikacin (36).  In a study performed in 2007 
in private healthcare facilities in South Africa, tobramycin was the most active 
aminoglycoside against A. baumannii (81% susceptible) (13). 
Resistance to the aminoglycosides is usually due to decreased affinity of the drug for its 
target, the bacterial ribosome, either by modification of the drug or the ribosome. The 
most common mechanism amongst these mechanisms is the enzymatic inactivation of 
the drug, usually by the production of aminoglycoside-modifying enzymes (AMEs) 
encoded by genes frequently located on transferable         elements (66). These 
enzymes are proteins that N-acetylate(acetyltransferases), phosphorylate 
(phosphotransferases), or adenylate (nucleotidyltransferases) the aminoglycoside, thus 
rendering the antibiotic inactive (Figure 3) (66). Some strains of acinetobacter contain 
several aminoglycoside resistance genes. In addition, many of these AMEs are found 
on genetic elements that are associated with additional resistance determinants. 
Previous research on isolated strains of A. baumannii  from Cape Town have shown the 
presence of the AAC(3’)-I and ANT(3’’)-I enzymes(104).  
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FIGURE 3: Major aminoglycoside-modifying enzymes target sites on kanamycin B.  
Kanamycin B is susceptible to the largest number of enzymes. Each group of enzymes inactivates 
specific sites, but each of these sites is susceptible to distinct isoenzymes (Roman numerals) with 
different substrate specificities. The main clinically used aminoglycosides on which these enzymes act are 
as follows: amikacin (A), dibekacin (Dbk), gentamicin (G), gentamicin B (GmB), kanamycin A (K), 
isepamicin (I), netilmicin (N), sisomicin (S),and tobramycin (T).  
Adapted from Mingeot-Leclercq, M-P, Glupczynski, Y, Tulkens, PM. Aminoglycosides: Activity and 
Resistance. Antimicrobial Agents and Chemotherapy. April 1999, 43(4): 727-737. 
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TABLE 3: Important aminoglycoside-modifying enzymes and the antibiotics modified. 
ENZYME AMINOGLYCOSIDE 
MODIFIED 
TYPE OF ENZYME/ 
LOCATION 
REFERENCE 
AAC(3)-Ia Gentamicin Acetyltransferase 
Class 1 integron  
(104) 
AAC(3)-IIa Gentamicin, tobramycin Acetyltransferase (104) 
AAC(6’)-Ib Tobramycin, amikacin Acetyltransferase 
Class 1 Integron 
(104) 
AAC(6’)-Ih, AAC(6’)-lad Tobramycin, amikacin Acetyltransferase 
Plasmid  
(61) 
APH(3’)-Ia Kanamycin Phosphotransferase (104) 
APH(3’)-VI Amikacin, kanamycin Phosphotransferase 
Mostly plasmid 
(62) 
ANT(2”)-Ia Gentamicin, tobramycin Nucleotidyltransferase (104) 
ANT(3’)-Ia Streptomycin Nucleotidyltransferase (104) 
The site of modification is indicated in parentheses. A Roman numeral and a letter are used to indicate 
the pattern of resistance that they confer and to their primary sequence, respectively.
  
 
Other mechanisms of resistance to aminoglycosides include efflux pumps (AdeABC and 
AbeM) (67, 71). More recently, the production of 16S rRNA methylases which are 
capable of modifying the 16S RNA molecule have been described as a mechanism of 
high level resistance to the clinically important aminoglycosides (27, 66, 125). 
 
6. ANTIBIOTIC SUSCEPTIBILITY TESTING IN THE CLINICAL MICROBIOLOGY 
LABORATORY 
Drug susceptibility testing is performed because it serves to guide choice of 
antimicrobial therapy. In addition, it serves as a predictor of patient outcome, as well as 
detection of some resistance markers. Susceptibility testing may be performed using a 
variety of validated methods: disk diffusion testing (Kirby-Bauer method), Epsilometer 
test, agar dilution and broth microdilution. Often diagnostic laboratories are under 
pressure from clinicians and hospital administrators to provide rapid and accurate 
bacterial identification and susceptibility results. To accomplish this, many laboratories 
have adopted the use of semi-automated and automated testing that have been 
designed to reduce laboratory turn-around time, increase efficiency and improve cost-
effectiveness (106). 
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Problems have, however, been detected in susceptibility testing of A. baumannii. A high 
level of major errors were detected in tetracycline testing when disc diffusion was 
compared to broth microdilution (108). In the same study, beta-lactam drugs posed a 
problem when interpreted by broth microdilution testing (108). Problems have also been 
reported with susceptibility testing of colistin (35). 
Several studies have shown drawbacks of automated systems, particularly with the 
identification and susceptibility testing of nonfermenting gram-negatives (58, 110, 119-
121). The testing of aminoglycosides using automated susceptibility tests has revealed 
varying results. In a study comparing the Phoenix System with the MicroScan 
Walkabout in terms of automated susceptibility of nonfermenting gram-negatives, there 
were 8.6% minor errors associated with amikacin, 14.2% minor errors associated with 
gentamicin, and 5.7% minor errors associated with tobramycin testing (106). However, a 
problem with this study was that disc diffusion, not broth microdilution, was used to 
resolve discrepant results (106). A recent study revealed susceptibility testing using the 
Vitek®2 showed false susceptibility to amikacin in A. baumannii harbouring the armA 
gene, which confers resistance to amikacin (51). Another recent study found that the 
Vitek®2 incorrectly reported a third of the isolates as falsely susceptible to amikacin (2). 
Errors reported by these systems can have serious consequences for the clinical 
outcome of patients. The accuracy of these tests becom s paramount as available 
treatments diminish. The results may encourage treatment with inactive agents, or 
falsely restrict therapeutic options.  
 
CONCLUSION 
This study was proposed to inform the diagnostic laboratory on whether the Vitek®2 
automated system is an accurate means of testing for tobramycin susceptibility in A. 
baumannii, particularly due to the paucity of published information about tobramycin 
susceptibility testing, and as tobramycin is frequently used to treat patients at our 
institution.  In addition, an assessment of the accuracy of the various methods in 
determining sensitivity is critical as inappropriate antimicrobial therapy is associated with 
increased morbidity and mortality. 
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Abstract 
Acinetobacter baumannii is a major pathogen causing nosocomial infections, particularly 
in critically ill patients.  This organism has acquired the propensity to rapidly develop 
resistance to most antibiotics. At several hospitals within Cape Town, tobramycin and 
colistin remain frequently the only therapeutic options. The Vitek®2 automated 
susceptibility testing (AST) is used in the clinical laboratory to determine selected 
susceptibility profiles. The suspicion of a possible AST-related technical error when 
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testing for susceptibility to tobramycin in A. baumannii precipitated this study. Thirty-
nine A. baumannii strains isolated from clinical specimens (June-December 2006) which 
exhibited MICs close to the tobramycin breakpoints were included in this prospective 
study. Tobramycin susceptibility testing by AST, disc diffusion, Epsilometer test and 
agar dilution was compared to broth microdilution (BMD), the reference method. 
Additionally, PCR was performed to detect the aac(3)-IIa gene which encodes an 
aminoglycoside modifying enzyme with activity against tobramycin. The tobramycin 
susceptibility results revealed errors in 25/39 isolates (10 very major and 15 minor errors) 
when AST was compared to BMD (p<0.001), 12/39 (1 very major and 11 minor errors) 
when Etest was compared to BMD, and 15 errors (3 very major and 12 minor errors) when 
disc diffusion was compared to BMD. Additionally, the tobramycin resistance gene, 
aac(3)-IIa was detected in 21/25 of the discrepant isolates, confirming the resistant 
phenotype detected by the reference method. Molecular typing showed that these 
isolates were genetically related. Clinical laboratories using the Vitek®2 system for 
routine use should consider an alternative susceptibility testing method to determine 
susceptibility to tobramycin.
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Acinetobacter baumannii has gained increased notoriety as a highly-resistant nosocomial 
pathogen globally. This organism has been associated with infections in immunocompromised 
and debilitated patients, particularly in the intensive care (ICU) setting (2, 14). 
 
This organism has proven to be a formidable adversary. Acinetobacter has the capacity for 
long-term survival in the hospital environment (4, 9). In addition, its remarkable capacity to 
acquire resistance has prompted its classification as a high priority pathogen by the 
Antimicrobial Availability Task Force of the Infectious Diseases Society of America (13). Pan 
drug-resistant phenotypes have been isolated in many settings (4, 5, 25). A. baumannii is 
endemic in some hospitals’ ICUs in the Western Cape, South Africa. The majority of these are 
multidrug-resistant organisms, retaining susceptibility only to tobramycin and colistin. 
Susceptibility rates for A. baumannii isolated from blood cultures in 2006 at our diagnostic 
laboratory revealed that only 55% and 57% remained susceptible to imipenem and meropenem, 
respectively. 
 
The pressure on clinical diagnostic laboratories to produce rapid identification and susceptibility 
profiles has resulted in increasing use of automated microbiology systems, such as the Vitek®2 
(bioMérieux).  Although there are many advantages to the use of this technology, several 
studies have indicated inaccurate results especially when testing non-fermenting gram-
negatives, such as A. baumannii (12, 24, 26-28). These inaccuracies have a major impact on 
patient management as they may encourage the use of inactive antimicrobials in critically ill 
patients. In addition, they promote the use of broader spectrum antibiotics if narrow spectrum 
drugs are falsely reported as resistant. Inaccuracies with AST have been reported in the 
literature regarding aminoglycoside testing  (1, 7). A recent study found that up to 1/3rd of A. 
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baumannii isolates (n=107) tested were incorrectly reported as susceptible to amikacin by the 
Vitek®2 instrument (1).  
 
A discrepancy between tobramycin susceptibility testing using manual methods and the Vitek®2 
automated susceptibility test method alerted the clinical diagnostic laboratory to a possible 
technical error, thus precipitating this study. A prospective study of A. baumannii to investigate 
the accuracy of tobramycin susceptibility testing in comparison to validated susceptibility test 
methods was conducted.  In addition, we hypothesised that the resistance was due to the 
aminoglycoside modifying enzyme, AAC(3)-IIa (aminoglycoside acetyltransferase), as the gene 
encoding this enzyme was previously isolated from clinical isolates of A. baumannii at our 
institution (3). Pulse-field gel electrophoresis and rep-PCR using the Diversilab was also 
performed to compare the clonal relatedness of these isolates.                                                                                                       
 
 
                                          MATERIALS AND METHODS 
 
The study was conducted in 4 phases. In phases I and II, the identification was performed, and 
AST results were compared to the reference broth microdilution. In phase III, the tobramycin 
resistance genotype was investigated. Finally, in phase IV, the molecular epidemiology of the 
strains was determined. 
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Bacterial strains. A total of 39 nonrecurring randomly collected clinical isolates of A. baumannii 
were tested. These isolates were obtained from 5 hospitals in Cape Town, South Africa (Groote 
Schuur Hospital, Red Cross Children’s Hospital, Victoria Hospital, Mowbray Maternity Hospital, 
and G.F. Jooste Hospital) over a 7 month period (June 2006-December 2006). Most of the 
isolates were obtained from various clinical specimens from patients in intensive care units, the 
majority being tracheal aspirates. The isolates selected had zone diameters or MICs close to 
the tobramycin breakpoints, as defined by the Clinical and Laboratory Standards Institute 
(CLSI). Appropriate quality control organisms (ATCC strains) were used for all susceptibility 
testing as per CLSI or manufacturer’s recommendations. The isolates were stored on beads 
(Viabank VIM tubes, Abtek Biologicals Ltd), and were passaged twice on 2% blood agar plates 
(Greenpoint  Media Laboratory, NHLS). 
 
Identification. All strains were identified twice by the Vitek®2 Gram-Negative Identification card 
(bioMérieux, LaBalme, France) according to manufacturer’s instructions at 0.6, and 1.0 
McFarland. A percentage probability above 90% was considered an acceptable identification.  
 
Susceptibility test methods. The susceptibilities of all isolates were tested by disc diffusion 
(Oxoid, Basingstoke) and Etests (AB Biodisk, Solna, Sweden) using cation-adjusted Mueller-
Hinton medium from three commercial manufacturers [bioMérieux (Randburg, South Africa), 
Bio-Rad Laboratories (Johannesburg, South Africa), and Greenpoint NHLS Media Laboratory 
(Cape Town, South Africa)] according to CLSI and manufacturer’s guidelines, respectively. 
These tests were performed with inocula from the same subculture. In addition, automated 
susceptibility using the Vitek®2 NO-22 susceptibility card (bioMérieux) was performed twice, at 
0.6 and 1.0 McFarland, respectively. The raw MICs obtained using the Vitek®2 was used for 
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analysis. Agar dilution and broth microdilution were performed on the isolates in duplicate by 
two different scientists at the Research and Development Division of bioMérieux (LaBalme, 
France) using cation-adjusted Mueller-Hinton medium. Results were interpreted using CLSI 
criteria. Discordant results with the reference method (BMD) were classified as very major 
errors, major errors, or minor errors. 
 
Quality control organisms included Pseudomonas aeruginosa ATCC27853 and Escherichia coli 
ATCC 25922 as recommended by CLSI and the manufacturer.  
 
PCR for detection of aac(3)-IIa. Genomic DNA from each isolate was extracted using the 
EasyMag (bioMérieux, Durham, North Carolina) as per manufacturer’s instructions. The quantity 
and quality of DNA extracted was confirmed using the Nanodrop® ND-1000 spectrophotometer 
(ranged between 8-78ng/µL).  Primers (F:  cgc gga agg caa taa c, R: gct tct caa gat agg tg) from 
previously published sequences were used (3).    A. baumannii strains, previously isolated at 
our laboratory and designated  MOS-1 and MOS-2, were used as positive and negative 
controls, respectively.(3) 
 
The mastermix consisted of magnesium chloride (25 mM), 2.5 mM of each dNTP, forward and 
reverse primers (20 pmoles each), and 2.5 U Taq polymerase in buffer made up to a final 
volume of 50 µL per reaction. An initial denaturation at 95 °C for 5 minutes, followed by 35 
cycles of 95 °C for 1 minute, 51 °C for 45 seconds, 72 °C for 1 minute, and a final extension at 
72 °C for  5 minutes was carried out. The final reaction products were separated on a 2 % 
agarose gel by gel electrophoresis, stained with ethidium bromide, and visualised under UV 
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light. The amplicon sizes were estimated using a 1 kb Plus DNA molecular weight marker 
(Invitrogen Life Science). A positive, negative, extraction control and water blank were included 
for each gel. PCR was repeated for all negative isolates. 
 
The amplicons from two isolates were sequenced by the DNA Sequencing Facility at the 
University of Stellenbosch, Cape Town, South Africa (ABI PRISM BigDye Terminator v3.1 
Ready Reaction Cycle Sequencing Kit using ABi genetic analysers) and blasted on Genbank to 
determine their nucleic acid similarity. 
 
Pulsed Field Gel Electrophoresis. The relatedness of the isolates was compared by pulsed-
field gel electrophoresis (PFGE) by an in-house protocol with minor modifications (3). Following 
plug preparation and cell lysis, the plugs were digested with Apa-1 (Roche) for two hours. The 
plugs were then separated on a 1.5 % PFGE agarose gel (BioRad) in 0.5X Tris buffer. The 
electrophoresis was carried out in a Gene Navigator® PFGE machine (Amersham Biosciences 
AB, Uppsala, Sweden) for 23 hours with the pulse time increasing from 5-45 s, after which it 
was stained with ethidium bromide, destained, and photographed using a Fotodyne Inc. UV light 
box and a Kodak EDAS 290 camera . The fingerprint images were analysed by Gel Compare II 
software Version 4.6 (Applied Maths, Sint-Martens-Latem, Belgium) using dice similarity index 
for cluster analysis and the unweighted pair group average (UPGMA) for tree building. All 
isolates with PFGE banding patterns with >87% similarity were grouped within the same cluster 
(11). Banding patterns were compared with 1.5% optimisation and 1.5% band position tolerance 
(11). 
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In addition, rep-PCR using the Diversilab (bioMérieux) was performed by the R&D Division, 
bioMérieux, La Balme, France. 
 
Statistical methods. The χ 2 test was used to examine the association of the various 
susceptibility testing methods and the reference method. In addition, the degree of correlation 
between the test method and the reference method was determined using unweighted kappa. 
Statistical tests were performed using an online statistical calculator 
(http://faculty.vassar.edu/lowry/vassarstats.html). A p-value <0.05 was considered statistically 
significant. 
 
Ethics. This research received approval from the University of Cape Town, Health Sciences 
Faculty, Research Ethics Committee. 
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                                       RESULTS and DISCUSSION 
 
Characterisation of clinical isolates. All 39 isolates were identified twice by the Vitek® 2 
instrument as A. baumannii with a high percentage probability( 99%). The identifications 
were also subsequently confirmed by API phenotype testing performed by the R&D Division, 
bioMérieux, La Balme, France. 
 
Tobramycin susceptibility and error rates. The susceptibilities of the isolates were 
determined by multiple manual and automated methods. The interpretative category errors 
that were used are defined as follows: very major error ((isolate susceptible by reference 
method is resistant by test method), and minor error (difference between reference method 
and test method differs by 1 interpretative category). An overall category agreement error 
rate of less than 10 % was considered an acceptable performance of a susceptibility test 
method, which included ≤ 1.5 % very major errors and ≤ 3.0 % major errors (10).  
 
The level of categorical agreement between the different methods and the reference method 
(BMD) varied widely and is shown in Table 1. A statistically significant number of very major 
(10 isolates) and minor errors (15 isolates) were observed when Vitek®2 AST was 
compared to BMD (p<0.001). Irrespective of the testing method, no major errors were 
detected (Figure 1). A recent study at the San Antonio Military Medical Centre, Texas, 
United States, revealed errors with manual and automated susceptibility testing of 
tobramycin (1). Very major errors were detected in 13.1% of isolates tested by Vitek®2, as 
compared to 2.8 % VMEs when disc diffusion and E-tests were compared to BMD. The 
authors also noted VMEs with tobramycin susceptibility testing using other automated 
systems as well. Our study found a higher level of VMES, with 25.6 % detected in isolates 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
63 
tested by the Vitek®2. The use of a higher inoculum when performing AST did not have an 
effect on the error rates. Although errors occurred with manual testing methods as well, we 
showed that the Etest correlated the best with the reference method (k 0.5169) (Table 2).  
 
Several studies have been conducted to evaluate automated methods for the detection of 
aminoglycoside resistance amongst non-fermenters, but few of these have looked at A. 
baumannii in particular. Most studies have detected problems with other aminoglycosides, 
such as amikacin (1, 5). The manufacturers of the Vitek®2 and other automated systems 
either suggest non-reporting or confirmation of the susceptibility result by manual methods in 
these cases. 
 
Detection of aac(3)-IIa. Previous research at our institution had established that the 
prevalent mechanism of tobramycin resistance amongst A. baumannii isolated at the clinical 
diagnostic laboratory was an aminoglycoside modifying enzyme encoded by the aac(3-)IIa 
gene (8). Based on this information, PCR for the aac(3-)IIa gene was performed on the 39 
isolates (Figure 2). Presence of the AAC(3)-IIa enzyme was inferred by demonstration of the 
gene. All isolates with a negative PCR result had a repeat PCR performed. In addition, a 
16sRNA PCR was performed on these isolates to confirm the integrity of bacterial DNA. 
 
Twenty-one of the twenty-five isolates that demonstrated discordant results (i.e. either 
sensitive or intermediate by Vitek, but resistant by BMD) were found to contain the aac(3)-IIa 
gene (Table 1).This confirmed a possible mechanism of resistance to tobramycin. This is not 
surprising as a worldwide study (which included isolates from South Africa) has shown that 
the AAC(3)-II enzyme was the commonest aminoglycoside modifying enzyme (AME) 
present, accounting for resistance to aminoglycosides in 50% of isolates tested(8). 
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Numerous aminoglycoside-modifying enzymes have been isolated from A. baumannii. The 
aac(3)-IIa gene confers resistance to gentamicin, tobramycin, dibekacin, netilmicin, and 
sisomicin. This resistance profile is common amongst the Enterobacteriaceae. The AAC(3)-
IIa enzyme is the commonest resistance mechanism in the group exhibiting this resistance 
profile, accounting for 84.8% of isolates (12). The aac(3)-IIa gene has been  detected in 
21.3% of Acinetobacter spp. (12).  
 
Another study concluded that AME genotype was an inadequate predictor of the 
aminoglycoside phenotype, suggesting that multiple resistance mechanisms were operating 
simultaneously (1). Although this may be true, our study showed a good correlation between 
the presence of the aac(3)-IIa gene and tobramycin resistance, with the gene being present 
in 12/19 (63 %) isolates with tobramycin MICs ≥16.  
 
Four isolates that were resistant to tobramycin by BMD lacked the aac(3)-IIa gene. These 
isolates likely have other mechanisms of resistance to tobramycin, such as AAC-6’ or ANT-
2”, combinations of AMEs, efflux pumps or other resistance mechanisms that were not 
explored further as this was not the focus of this study. Importantly, though, the failure of the 
Vitek2 to detect these resistant isolates suggests a wider failure of the system to detect 
tobramycin resistance. 
 
Alarmingly, another study showed that susceptibility to tobramycin was retained in the 
presence of a potentially inactivating AME gene in 8 (21.6 %) of isolates (1). We found that 
just a single isolate that was susceptible by all test methods harboured the aac(3)-IIa gene.  
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Amplicons from two isolates (17 and 28) were sequenced and blasted.  A comparison of the 
sequencing data showed that they were 100% identical to the corresponding sequence of 
the aac(3)-IIa gene. In addition, all the AAC(3) enzymes that confer resistance to tobramycin 
have a conserved threonine residue at position 74 (12). Conversion of the nucleotide 
sequences to amino acid residues confirmed that the isolates selected had a threonine 
residue at position 74. 
 
Our hypothesis to explain the discrepant Vitek® 2 results is that the catalytic activity of the 
AAC(3)-IIa enzyme is too slow to be detected by rapid automated susceptibility test 
methods, particularly with a poor substrate like tobramycin (6). Whether this has implications 
on the clinical outcome of patients treated with tobramycin has yet to be determined. 
 
Relatedness of isolates. The majority of clinical strains were isolated from various intensive 
care units from 4 different hospitals. The isolates were recovered from patients aged 4 days 
to 63 years (mean 29.37 years), with an equal male to female ratio (1.06:1). The isolates 
were recovered from a variety of clinical specimens, which included blood cultures (n=4), 
tracheal aspirates /sputum (n=21), pus swabs (n=7), urine (n=5), and tissue/fluid cultures 
(n=3). 
 
The relatedness of the isolates was determined by rep-PCR using the Diversilab 
(bioMérieux) system. The isolates clustered into 4 clones (Figure 3), with the majority of 
isolates clustering in Cluster C. The results of the Diversilab confirmed the presence of a 
predominant clone that was not confined to a single hospital (Table 3). In addition, isolates 3, 
4 and 11 (which lacked the AAC(3’)-IIa enzyme but were resistant to tobramycin), were 
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scattered across clusters C and D, confirming that tobramycin resistance was not linked to a 
single clone at our institution. 
 
Pulsed field gel electrophoresis was performed to compare a representative of the two 
commonest clones (C and A) with the dominant strains that had previously been isolated at 
our institution (Figure 4). The MOS-1 and MOS-2 strains were isolated from the same patient 
during the same period of hospitalisation at Groote Schuur Hospital (3). Isolate C2 was 
highly similar to MOS-1, a tobramycin resistant strain with the aac(3)-IIa gene, that had been 
present in Cape Town since the early 1980s (3). Although it might have been expected that 
the tobramycin resistant strains had recently emerged due to the increased use of 
tobramycin at our hospitals, PFGE suggests that is unlikely. 
 
                                                     CONCLUSION 
According to our knowledge, this is the first study in South Africa that has assessed the 
ability of the VITEK®2 to detect A. baumannii isolates with reduced susceptibility to 
tobramycin. Tobramycin, tigecycline and colistin remain the only antibiotics available in the 
public health sector that are effective against the multidrug resistant strains of A. baumannii 
in the Western Cape, South Africa. Thus, accurate susceptibility testing remains critical. 
 
The data from our study confirms the limitations of both automated and manual tobramycin 
susceptibility test methods. In conclusion, the VITEK® 2 appears to be unreliable for the 
detection of tobramycin resistance in A. baumannii. It appears that manual methods, such as 
E-tests, may be more reliable for susceptibility testing when tobramycin is considered as a 
potential therapeutic agent. 
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TABLE 1. Tobramycin susceptibility testing results of the 39 isolates using different 
methods. 
Isolate Disc Diffusion (mm) Etest (MIC in µg/ml) Agar dilution (MIC µg/ml) Vitek 0.6McF (MIC µg/ml) Broth Microdilution (MIC µg/ml) aac(3)-IIa  gene
7 0mm 256 128                               >=16                                       >256 Absent
40 4mm 8 4 4                                       >256 Present
3 3mm 32 16 8 256 Absent
4 10mm 16 8 8 256 Absent
27 0mm 64 32                               >=16 256 Absent
31 12mm 16 16 4 256 Present
18 13mm 16 4 8 128 Present
36 13mm 8 16 4 128 Present
38 0mm 32 16                               >=16 128 Absent
10 13mm 16 4 8 64 Present
5 11mm 8 8 8 32 Present
6 14mm 4 2 2 32 Present
11 13mm 16 4 2 32 Absent
12 9mm 32 8 8 32 Present
13 11mm 32 4 4 32 Present
17 13mm 16 2 4 16 Present
22 16mm 8 2                                 <=1 16 Present
23 21mm 2                               <=0.5                                 <=1 16 Absent
39 15mm 8 2 2 16 Present
8 13mm 8 4 4 8 Present
9 15mm 8 2 2 8 Present
14 14mm 8 4 2 8 Present
15 15mm 8 4 4 8 Present
20 15mm 4 2                                 <=1 8 Present
26 0mm 64 2                               >=16 8 Present
32 17mm 4 2                                 <=1 8 Present
33 10mm 16 8 4 8 Present
42 14mm 8 4 2 8 Present
29 14mm 8 2 2 4 Absent
24 22mm 2                               <=0.5                                 <=1 2 Absent
35 21mm 2                               <=0.5                                 <=1 2 Absent
2 19mm 2                               <=0.5                                 <=1 1 Absent
16 23mm 2                               <=0.5                                 <=1 1 Absent
21 15mm 2                               <=0.5                                 <=1 1 Absent
28 23mm 1                               <=0.5                                 <=1 1 Present
30 20mm 2                               <=0.5                                 <=1 1 Absent
34 23mm 1                               <=0.5                                 <=1 1 Absent
37 21mm 2                               <=0.5                                 <=1 1 Absent
41 21mm 2                               <=0.5                                 <=1 1 Absent  
KEY: 
Red-indicates resistant susceptibility results , blue-intermediate, green-susceptible. 
The blocks highlighted in yellow indicate isolates with discrepant results with confirmed 
presence of aac(3)-11a gene. 
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FIGURE 1. Graph of absolute number of errors detected when each susceptibility test 
method was compared to BMD. 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
70 
 
 
 
 
TABLE 2. Statistical analysis of the susceptibility test results. 
 
 
Chi-squared P-value Unweighted Kappa Confidence level(k)
Vitek vs BMD 18.48 <0.0001 0.0905 0-0.3041
Agar vs BMD 16.78 0.0002 0.2215 0-0.4477
DD vs BMD 2.92 0.2322 0.3858 0.1547-0.6169
Etests vs BMD 1.32 0.5169 0.5329 0.313-0.7528  
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FIGURE 2. Gel electrophoresis for the detection of the presence of amplicons for specimens 
21-30. 
Lane 1: Molecular weight mark, Lanes 1-11: Specimens 21-30, Lane 12: Positive control, 
Lane 13: Negative control, Lane 14: Extraction control, Lane 15: Blank. 
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FIGURE 3: Results of Diversilab typing of the 39 isolates as provided by the R&D Division, 
bioMérieux. 
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TABLE 3. Stratification of Diversilab clusters by hospital and ward. 
 
                                                                                                                                                Distribution of strains across hospitals [no. (%)]
                                                                    Groote Schuur Hospital                  Red Cross Mow GFJ Vict
Diversilab cluster (no.) C27 D12 E26 D22 D13 Others C1 Others
A (6) 1(16.67) 1(16.67) 2(33.33) 1(16.67) 1(16.67)
B(4) 1(25) 1(25) 1(25) 1(25)
C(26) 6(23.08) 4(15.38) 2(7.69) 1(3.84) 4(15.38) 8(30.77) 1(3.84)
D(3) 1(33.33) 1(33.33) 1(33.33)  
 
Key: C27- Adult Medical ICU, D12- Adult Surgical ICU, E26- Adult Isolation ICU, D22- Adult 
Cardiothoracic ICU, D13- Adult Neurosurgical ICU, C1- Paediatric ICU, Mow- Mowbray 
Maternity Hospital, GFJ- G. F. Jooste Hospital (secondary level hospital), Vict- Victoria ICU 
(secondary level hospital). 
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FIGURE 4. Results of PFGE comparing 2 representative isolates of the commonest 
Diversilab clones, A and C; and MOS-1. 
A2: Isolate 16, RUH3: control strain, MOS1: clinical strain with aac(3)-IIa, C2: Isolate 32, 
MOS-2: clinical strain  without aac(3)-IIa. 
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APPENDIX 1: Ethics Approval obtained from University of Cape Town, Health Sciences 
Faculty, Research Ethics Committee. 
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APPENDIX 2: Budget 
 
Reagents and susceptibility testing material will be sponsored by BioMerieux and Omnimed. 
 
TABLE 1: Estimated cost of consumables 
 
 Cost(unit) Total cost 
ANTIBIOTIC DISKS 
Gentamicin 
 
R0.23 
 
R35.05 
Amikacin R0.23 R35.05 
Tobramycin R0.23 R35.05 
ETESTs 
Gentamicin 
 
R29.01 
 
R4351.50 
Amikacin R29.01 R4351.50 
Tobramycin R29.01 R4351.50 
Vitek®2  CARDS 
GN Identification cards 
 
R40 
 
R2000 
No22 Susceptibility cards  
R40 
 
R2000 
TOTAL  R17 159.65 
 
The reagents and equipment utilised for the molecular aspects of the study will be obtained from the 
National Health Laboratory Services and the Department of Medical Microbiology, Institute of 
Infectious Diseases and Molecular Medicine, University of Cape Town. 
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APPENDIX 3: Data collation  
 
3.1 Selection of isolates  
 
TABLE 2:  Isolates collected in diagnostic laboratory from June – December 2006. 
AGE/GENDER INCLUDED VIABILITY OF ISOLATE REASON FOR EXCLUSION CODE      
68/F Yes Viable   15 
38/F Yes Viable   12 
55/M Yes Viable   24 
66/F Yes Viable   8 
44/F Yes Viable   4 
5m/M No Non-viable Non-viable  
18m/M No Non-viable Non-viable  
18m/M No Non-viable Non-viable  
50/M Yes Viable   23 
50/M No Viable Duplicate  
44/M No Non-viable Non-viable  
4d/F Yes Viable   28 
59/F Yes Viable   27 
28/F No Non-viable Non-viable  
6m/M Yes Viable   5 
34/M No Viable P. putida  
26/M No Viable Duplicate  
26/M Yes Viable   9 
37/M Yes Viable   42 
17/F No Non-viable Non-viable  
24/M Yes Viable   31 
28/M No Non-viable   
22/F Yes Viable   25 
60/M No Non-viable Non-viable  
66/M No Non-viable Non-viable  
63/M Yes Viable   22 
25/M No Non-viable Non-viable  
15/F No Non-viable Non-viable  
51/M No Non-viable Non-viable  
4m/F No Non-viable Non-viable  
46d/M Yes Viable   7 
55/M Yes Viable   21 
7m/F Yes Viable   10 
31/F Yes Viable   26 
44/F Yes Viable   38 
10m/M No Non-viable Non-viable  
50/F No Non-viable Non-viable  
45/M Yes Viable   11 
37/F Yes Viable   2 
19/M No Non-viable Non-viable  
43/F No Non-viable Non-viable  
49/M Yes Viable   39 
25/M No Non-viable Non-viable  
13/F Yes Viable   16 
15/M Yes Viable   30 
35/M No Non-viable Non-viable  
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45/F No Non-viable Non-viable  
7d/F No Non-viable Non-viable  
15d/F Yes Viable   18 
29d/F No Non-viable Non-viable  
65d/F No Non-viable Non-viable  
75d/F No Non-viable Non-viable  
14/F Yes Viable   13 
14/F No Viable Duplicate  
26/M No Non-viable Non-viable  
84d/M Yes Viable   34 
Outbreak Yes Viable Duplicate  
 Outbreak Yes Viable   36 
 Outbreak Yes Viable   40 
 Outbreak Yes Viable   35 
24d/F Yes Viable   17 
27/F Yes Viable   33 
11m/M Yes Viable   29 
46/M Yes Viable   41 
22/M Yes Viable   20 
56d/F Yes Viable   14 
33/F No Non-viable Non-viable  
33/F No Non-viable Non-viable  
34/F Yes Viable   37 
4m/F No Non-viable Non-viable  
19/F No Viable A.haemolyticus  
12/M No Non-viable Non-viable  
19/M Yes Viable   32 
37/M Yes Viable   6 
69/F No Non-viable Non-viable  
69/F No Non-viable Non-viable  
45/M Yes Viable   3 
 
 
N.B. Rows highlighted in yellow indicate isolates used in the study. 
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3.2  Clinical data of isolates selected 
 
TABLE 3: Clinical data of patients from whom strains were isolated 
 
NO. AGE/GENDER WARD DIAGNOSIS SPEC 
TYPE 
DATE OF 
COLLECTION 
PURE/ 
MIXED 
culture 
VITEK/ 
MANUAL 
susceptibility  
testing 
02 37/F C27 Resp failure culba 17/08 Pure Manual 
03 45/M E26 Polytrauma culpu 10/07 Pure Vitek 
04 44/F C27 Pneumonia cultr 24/07 Pure Vitek 
05 6month/M C1 ICU AVSD cultr 23/07 Pure Vitek 
06 37/M G5 Pyrexia culsp 2/10 Pure Vitek 
07 46 day/M C1 ICU Pneumonia cultr 2/10 Pure Vitek 
08 66/F D13 Subarachnoid 
haemorrhage 
cultr 23/10 Pure  Vitek 
09 26/M C27 Stab cultr 16/10 Pure Vitek 
10 7 month/F C1 ICU Pneumonia culsp 06/09 Pure Vitek 
11 45/M D12 Head injury cultr 09/10 Mixed with 
K.pneumo 
Vitek 
12 38/F D22 Post surgery cultr 16/10 Mixed; NF Vitek 
13 14/F C1 ICU Liver  
transplant 
culsp 09/10 Mixed with 
K.pneumo 
Vitek 
14 56 day/F C1 ICU Pneumonia culsp 17/10 Mixed; NF Vitek 
15 68/F D24 Post surgery culpu 21/07 Mixed with 
Entero- 
coccus 
Vitek 
16 13/F B1 Bronchiolitis culsp 22/09 Pure Vitek 
17 24 day/F Mow 
NICU 
Sepsis cultr 17/10 Pure Vitek 
18 15 day/F C1 ICU Pneumonia culur 04/07 Mixed with 
yeast, 
CNS 
Vitek 
20 22/M C27 Pneumonia cultr 16/10 Pure Vitek 
21 55/M D22 Post surgery cultr 09/10 Mixed, NF Vitek 
22 63/M C27 Renal failure cultr 09/10 Pure Vitek 
23 50/M Vict 
ICU 
GSW culba 27/08 Pure Manual 
24 55/M D22 Post cardiac 
surgery 
culur 04/12 Pure Vitek 
25 22/F D12 Polytrauma culur 04/12 Pure Vitek 
26 31/F D12 Polytrauma culur 04/12 Pure Vitek 
27 59/F D12 Post surgery culpu 04/12 Mixed; 
E.cloacae 
Vitek 
28 4 day/F C1 ICU Post surgery cultr 05/12 Pure Vitek 
29 11 day/M C1 ICU Pneumonia culba 05/12 Pure Manual 
30 15/M GJF Septic wound culpu 21/08 Mixed; 
S.aureus 
Manual 
31 24/M D12 Polytrauma  culti 06/11 Pure Vitek 
32 19/M C27 Post surgery cultr 23/10 Mixed; NF Vitek 
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33 27/F F25 Myeloprolifer-
ative 
disorder 
culfl 21/10 Mixed; 
S.aureus 
Vitek 
34 84 day/M  C1 ICU Necrotising 
fasciitis 
culsp 17/07 Mixed; NF Vitek 
35 Outbreak 
investigation 
D12  culpu 18/08 Pure Manual 
36 Outbreak 
investigation 
C1 ICU  culpu 18/08 Pure Manual 
37 34/F G23 TENS culsp 05/11 Mixed; NF Vitek 
 
38 44/F C27 Pneumonia cultr 02/11 Mixed; NF Vitek 
39 49/M F7 Abscess culti 27/10 Pure Vitek 
40 Outbreak C1 ICU  culpu 18/08 Pure Manual 
41 46/M C27 COPD culba 19/08 Pure Manual 
42 37/M D12 Polytrauma culur 23/10 Pure Vitek 
 
Key: This data was obtained from the NHLS Laboratory Information System. 
M – male, F- female.  
Wards: C27- adult medical intensive care unit (ICU) (Groote Schuur Hospital),E26- adult isolation 
ICU(Groote Schuur Hospital), C1 ICU- paediatric ICU(Red Cross Children’s Hospital), G5- adult 
medical ward(GSH), D13- adult neurosurgical ICU(GSH), D22- adult cardiothoracic ICU(GSH), D24-
adult cardiothoracic ward(GSH),B1- paediatric medical ward(RXH), MOW NICU- neonatal ICU 
(Mowbray Maternity Hospital),VICT ICU- adult ICU(Victoria Hospital), GFJ- general male ward, GF 
Jooste Hospital, F25- adult vascular surgery ward, G23- adult dermatology ward,F7- adult 
neurosurgical ward. 
Specimens: Culba- blood culture, Culur- urine culture, Culti- tissue culture, Culsp- sputum culture, 
Culpu- Pus swab culture,Cultr- Tracheal aspirate culture, Culfl- Sterile fluid culture. 
Organisms: CNS – coagulase-negative staphylococcus, NF- normal flora. 
 
ANALYSIS OF SAMPLE INFORMATION : 
 
Patient profiles: 
 
Ages ranged from 4day-63 years (Mean age 29.37) 
 
Gender profile Male: Female = 1.06:1 (19:18) 
 
Wards 
Majority ICUs 33(including 3 outbreak specimens) 82.5% 
Respiratory ICU GSH 8      (20%) 
Surgical ICU GSH      7       (17.5%) 
Isolation ward GSH       1     (2.5%) 
Cardiothoracic ICU  GSH  3  (7.5%) 
Neurosurgical ICU  GSH  1   (2.5%) 
Paediatric ICU RXH  11     (27.5%) 
NICU Mowbray     1           (2.5%) 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
85 
ICU Victoria          1            (2.5%)           
General wards  7 (17.5%) 
General medical ward 1 (2.5%) 
Cardiothoracic ward 1 (2.5%) 
Paediatric high care 1 
Vascular surgery ward 1 
Dermatology ward 1 
ENT ward 1 
Surgical ward GFJ 1 
 
Medical conditions 
 
Respiratory (eg pneumonia) 11 (27.5%) 
Trauma-related 8 (20%) 
Surgery 8 (20%) 
Cardiac 1 (2.5%) 
Sepsis 5  (12.5%) 
Vascular 1 (2.5%) 
Renal 1 (2.5%) 
Myeloproliferative disorder 1 (2.5%) 
TENS 1 (2.5%) 
 
Specimen types 
Blood culture 4 (10%) 
Pus swabs 7 (17.5%) 
Tracheal aspirates/sputum 21 (14 tracheal apirates) (52.5%) 
Urine 5 (12.5%) 
Tissue culture 2 (5%) 
Fluid culture 1 (2.5%) 
 
Mixed/Pure cultures 
Pure 26 (65%) 
Mixed 14 [with other organisms(pathogens and n rmal flora)] 
 
ANALYSIS OF DATA: 
 
TABLE 4: Source of isolates 
 
TYPE OF ICU NUMBER OF 
ISOLATES 
PERCENTAGE OF ICU ISOLATES 
Respiratory 8 20 
Surgical 7 17.5 
Isolation 1 2.5 
Cardiothoracic 3 7.5 
Neurosurgical 1 2.5 
Paediatric 11 27.5 
Neonatal ICU  
Mowbray 
1 2.5 
ICU Victoria 1 2.5 
TOTAL 33 82.5 
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FIGURE 1: Graphic representation of isolates and the ICUs they were obtained from. 
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3.3 Original antibiotic susceptibility testing as performed by the clinical diagnostic laboratory 
 
TABLE 5: Antibiotic susceptibility results of isolates selected. 
  
KEY: NT- not tested, R- resistant, I- intermediate, S-susceptible. 
ANTIBIOTICS: PITZ-piperacillin-tazobactam, CTAZ- ceftazidime, CPIME- cefepime, GENT- 
gentamicin, AMIK- amikacin, IMI- imipenem, MERO- meropenem, CIP- ciprofloxacin, TS- 
trimethoprim-sulphamethoxazole, COL- colistin. 
 
 
 
 
 
 
 
 
 
ISOLATE PITZ CTAZ CPIME GENT AMIK IMI MERO CIP TS COL 
2 R R R R R R R R R S 
3 R R R R R R R R R S 
4 R I R R R R R R R S 
5 R I R R R R R R R S 
6 R I R R R R R R R S 
7 R I R R R R R R R S 
8 R I R R R R R R R S 
9 R I R R R R R R R S 
10 R R R R R R R R R S 
11 R R R R R R R R R S 
12 R R R R R R R R R S 
13 R R R R R R R R R S 
14 R I R R R R R R R S 
15 R R S R R S S R R S 
16 R S R S R R R S S NT 
17 R R R R R R R R R S 
18 R I R R R R R R R S 
20 R R R R R R R R R S 
21 S S S S R S S S S NT 
22 R I R R R R R R R S 
23 R R R R R R R R R S 
24 R R R R S R R R R NT 
25 R R R R R R R R R S 
26 R R R R R R R R R S 
27 R R R R R R R R R S 
28 R I R R R R R R R S 
29 R R R R R R R R R S 
30 S R S R R S S R R NT 
31 R I R R R R R R R S 
32 R R R R R R R R R S 
33 R R R R R R R R R S 
34 R I R R R R R R R S 
35 R R R R R R R R R NT 
36 R I R R R R R R R NT 
37 R R R R R R R R R S 
38 R S R R R R R S S S 
39 R R R R R R R R R S 
40 R I R R R R R R R NT 
41 R R R R S R R R R S 
42 R R R R R R R R R S 
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IDENTIFICATION AND 
SUSCEPTIBILITY TESTING  
 
 
 
 
 
 
 
 
 
Please note that although isolate 25 had some susceptibility tests performed, the remaining tests 
were not performed as the isolate was not stored on beads in error. The isolate was removed from 
further analysis. 
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APPENDIX 4.1: Identification of isolates and susceptibility test results 
 
SOP 1: Identification and susceptibility testing using the Vitek 2  
 
Day 1  
Single colony plates (2% blood agar) are streaked out to obtain fresh single colonies and to exclude 
mixed cultures. The plates are incubated at 35ºC for 18-24 hours. 
 
Day 2 
 
VITEK:  
 
MATERIALS:    VITEK2 DENSICHEK Kit                                             
                          VITEK 2 Cassette 
                          0.45 % sterile saline, pre-warmed                     
                          12 x 75 mm clear plastic disposable test tubes 
                           sterile sticks                    
                          Gram-negative ID cards 
                          No 22 susceptibility cards 
                          Purity plates – MacConkey agar 
 
 
METHOD:  
 
1. Aseptically  transfer  3.0 ml  of  sterile  saline  into  a  clear  plastic  test  tube.  
2. Select isolated colonies from the single colony plate. 
3. Use a sterile stick to transfer a sufficient number of morphologically similar colonies to the saline 
tube. Prepare the organism suspension with a density equivalent to 0.6McFarland using the 
VITEK2 DENSICHEK (bioMérieux, Durham, NC). 
4. Place the suspension tube, ID card and No22 susceptibility card in the cassette. 
5. Enter specimen data and load cassette into Vitek2 machine within 30 minutes. 
6. Repeat procedure using organism suspension of 1.0 McFarland. 
  
QUALITY CONTROL 
Vitek GN ID cards utilised:  BioMerieux, Lot 241019940, Expiry date 01/07/2007. 
Results of QC strains (ATCC 27853 and ATCC 25922 are shown in the results table on the following 
page. 
 
REFERENCES: 
Biomerieux, Vitek®2 ID-GNB Product Information Manual 
 
OTHER INFORMATION: 
 
Vitek®2 AST- NO22 Gram Negative Susceptibility Card, package insert, REF 22031. 
 
Vitek AST-NO22 Card Antibiotic Concentrations 
Gentamicin 4, 16, 32 µg/ml 
Amikacin 8, 16, 64 µg/ml 
Tobramycin 8, 16, 64 µg/ml  
 
QUALITY CONTROL 
Performed as per manufacturer’s recommendation. 
 
TABLE 6: MICs for quality control organisms using the Vitek 2 
 Amikacin 
  MIC 
Gentamicin 
     MIC 
Tobramycin 
       MIC 
 E.coli  
ATCC 25922 
< 2 – 4    < 1  < 1 
P.aeruginosa 
ATCC 27853 
< 2 – 4    < 1 - 2   < 1 
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TABLE 7: Results of identification of the 40 isolates using Vitek2 at 0.6 and 1.0 McF, 
respectively. 
 
SPECIMEN NUMBER IDENTIFICATION CONFIDENCE INTERVAL 
   
2 (0.6 McF) Acinetobacter baumannii Excellent (99.0) 
    (1.0 McF) Acinetobacter baumannii Excellent (99.0) 
3 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
4 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
5 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
6 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
7 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
8 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Very Good (94.70) 
CONTROL  ATCC 27853 Pseudomonas aeruginosa Excellent(98.24) 
 Pseudomonas aeruginosa Excellent(98.24) 
                    ATCC 25922 Escherichia coli Very Good(95.0) 
 Escherichia coli Very Good(95.0) 
9 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
10 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
11 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
12 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
13 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
14 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
15 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
16 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
17 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
18 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
20 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
21 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
22 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
23 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
24 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
25 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
26 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
27 Acinetobacter baumannii Excellent (99.0) 
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 Acinetobacter baumannii Excellent (99.0) 
28 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
29 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
30 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
31 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
32 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
33 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
34 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
35 Acinetobacter baumanii Excellent (98.79) 
 Acinetobacter baumannii Excellent (99.0) 
36 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
37 Acinetobacter baumanii Excellent (98.79) 
 Acinetobacter baumanii Excellent (98.79) 
38 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
39 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
40 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
41 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
42 Acinetobacter baumannii Excellent (99.0) 
 Acinetobacter baumannii Excellent (99.0) 
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TABLE 8: Results of antibiotic susceptibility testing using the Vitek2 AST at 0.6 and 1.0 McF, 
respectively. 
 
                    RESULTS OF  MICs OBTAINED FROM VITEK2 AUTOMATED SUSCEPTIBILITY TESTING
                VITEK 0.6 McFARLAND         VITEK 1.0 McFARLAND
ISOLATE GENTAMICIN AMIKACIN TOBRAMYCIN ISEPAMICIN NETILMICIN MECHANISM aacC2a GENTAMICIN AMIKACIN TOBRAMYCIN ISEPAMICIN NETILMICIN
2                >=16 32                 <=1                >=64 2 Inconsistent G,I Absent                >=16          >=64                  <=1          >=64 4 Consistent
3                >=16 32 8                >=64 2 Consistent G,I Absent                >=16          >=64                >=16          >=64 4 Consistent
4                >=16           >=64 8                >=64               >=32 Consistent G,A,I,N Absent                >=16          >=64 8          >=64           >=32 Consistent
5                >=16           >=64 8                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64 8          >=64           >=32 Consistent
6                >=16           >=64 2                >=64 16 Consistent G,A,I Present                >=16          >=64 2          >=64 16 Consistent
7                >=16           >=64                >=16                >=64 16 Consistent G,A,T,I Absent                >=16          >=64                >=16          >=64 16 Consistent
8                >=16           >=64 4                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64 4          >=64           >=32 Consistent
9                >=16           >=64 2                >=64 16 Consistent G,A,I Present                >=16          >=64                  <=1          >=64 16 Consistent
10                >=16           >=64 8                >=64               >=32 Consistent G,A,I,N Present                >=16 32 4          >=64           >=32 Consistent
11                >=16           >=64 2                >=64 16 Consistent G,A,I Absent                >=16          >=64 4          >=64 16 Consistent
12                >=16           >=64 8                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64 8          >=64           >=32 Consistent
13                >=16 32 4                >=64               >=32 Consistent G,I.N Present                >=16 32 2          >=64           >=32 Consistent
14                >=16           >=64 2                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64 2          >=64           >=32 Consistent
15                >=16 32 4                >=64               >=32 Consistent G,I,N Present                >=16          >=64 2          >=64           >=32 Consistent
16                 <=1           >=64                 <=1                >=64 2 Inconsistent A,I Absent                 <=1          >=64                  <=1          >=64 2 Inconsistent
17                >=16 32 4                >=64               >=32 Consistent G,I,N Present                >=16 32 4          >=64           >=32 Consistent
18                >=16           >=64 8                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64 4          >=64           >=32 Consistent
20                >=16           >=64                 <=1                >=64 16 Consistent G,A,I Present                >=16          >=64                  <=1          >=64 16 Consistent
21                 <=1           >=64                 <=1                >=64 2 Inconsistent A,I Absent                 <=1          >=64                  <=1          >=64 2 Inconsistent
22                >=16           >=64                 <=1                >=64 16 Consistent G,A,I Present                >=16          >=64                  <=1          >=64 16 Consistent
23                >=16 16                 <=1                >=64 2 Consistent G,I Absent                >=16 16                  <=1          >=64 2 Consistent
24                >=16            <=2                 <=1 2 4 Consistent G Absent                >=16            <=2                  <=1 2 4 Consistent
25                >=16 32                 <=1                >=64 4 Consistent G,I NT                >=16 32                  <=1          >=64 4 Consistent
26                >=16           >=64                >=16 32 16 Consistent G,A,T,I Present                >=16          >=64                >=16          >=64 16 Consistent
27                >=16           >=64                >=16                >=64 4 Consistent G,A,T,I Absent                >=16          >=64                >=16          >=64 4 Consistent
28 8           >=64                 <=1                >=64 2 Inconsistent A,I Present                 <=1          >=64                  <=1          >=64 2 Inconsistent
29                >=16           >=64 2                >=64               >=32 Consistent G,A,I,N Absent                >=16          >=64 2          >=64           >=32 Consistent
30                >=16 32                 <=1                >=64 2 Inconsistent G,I Absent                >=16 32                  <=1          >=64 2 Inconsistent
31                >=16           >=64 4                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64 4          >=64           >=32 Consistent
32                >=16           >=64                 <=1                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64                  <=1          >=64           >=32 Consistent
33                >=16           >=64 4                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64 2          >=64           >=32 Consistent
34                 <=1            <=2                 <=1                 <=1                 <=1 Consistent Absent                 <=1            <=2                  <=1             <=1             <=1 Consistent
35                >=16 16                 <=1                >=64 4 Consistent G,I Absent                >=16 16                  <=1          >=64 2 Consistent
36                >=16           >=64 4                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64 4          >=64           >=32 Consistent
37                >=16 16                 <=1                >=64 4 Consistent G,I Absent                >=16 16                  <=1          >=64 2 Consistent
38                >=16           >=64                >=16                >=64 2 Consistent G,A,T,I Absent                >=16          >=64                >=16          >=64 2 Consistent
39                >=16           >=64 2                >=64 8 Consistent G,A,I,N Present                >=16          >=64 2          >=64 16 Consistent
40                >=16           >=64 4                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64 4          >=64           >=32 Consistent
41                >=16            <=2                 <=1                 <=1 2 Consistent G Absent                >=16            <=2                  <=1 2 4 Consistent
42                >=16           >=64 2                >=64               >=32 Consistent G,A,I,N Present                >=16          >=64 2          >=64 16 Consistent
QC: P. aeruginosa ATCC 27853                 <=1            <=2                 <=1                 <=1                 <=1 Consistent                 <=1            <=2                 <=1              <=1             <=1 Consistent
QC: E.coli ATCC 25922                 <=1            <=2                 <=1                 <=1                 <=1 Consistent                 <=1            <=2                 <=1              <=1             <=1 Consistent
S 30
I 6
R 4
TOTAL 40  
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SOP 2: Disc Diffusion Testing 
 
MATERIAL:  Mueller-Hinton agar (3 different brands: BioRad, BioMerieux,Greenpoint) 
                      Antibiotic discs(Oxoid)- Gentamicin (10 µg)  
                                                            Amikacin    (30 µg) 
                                                            Tobramycin(10µg) 
 
METHOD:  
1. Select isolated colonies from single colony plate. 
2. Using  a  sterile  stick  to  transfer  a  sufficient  number  of  morphologically similar  colonies  
to  the  saline  tube. Prepare the organism suspension with a density equivalent to 
0.5McFarland. 
3. Whirl  out  suspension  on  to  Muller Hinton agar(MHA) (x 3  different  brands  of  MHA). 
4. Leave  for  3-5  minutes  to  allow  for  any  excess  surface  moisture  to  be absorbed. 
5. Apply aminoglycoside-impregnated discs using disc tabbing device. Each disc must be 
pressed down to ensure complete contact with the agar surface. The discs must be evenly 
distributed (>24mm from centre to centre). 
6. Invert plates and incubate within 15 minutes at 35 degrees Celsius under aerobic conditions 
for 24 hrs. 
 
 
READING PLATES AND INTERPRETING RESULTS: See Performance Standards for Antimicrobial 
Susceptibility Testing; 16
th
 Informational Supplement, M100-S16, Vol. 26 No.3, January 2006, CLSI. 
 
 
1. After 18-24 hrs of incubation, examine each plate. The zones of inhibition will be uniformly 
circular and there will be a confluent lawn of growth. If individual colonies are visible, the 
inoculum was too light and the test must be repeated. 
 
2. Measure the diameters of the zones of complete inhibition, including the diameter of the disc. 
Measure the zones to the nearest millimetre, using a sliding caliper, which is held on the back 
of the inverted petri plate. 
 
3. The zone margin is considered the area showing no obvious, visible growth that can be 
detected with the unaided eye. If any discrete colonies appear within the zone of inhibition, 
the test will be repeated with a pure culture. If colonies continue to grow within the zone of 
inhibition, measure the colony-free inner zone. 
 
4. The sizes of the zones must be interpreted according to Table 2B2   (Performance Standards 
for Antimicrobial Susceptibility Testing; 16
th
 Informational Supplement, M100-S16, Vol. 26 
No.3, January  2006,  CLSI.)  
 
 
 
 
FIGURE 2: Example of disc 
diffusion testing on Mueller-Hinton 
agar 
 
Image downloaded from: 
diverge.hunter.cuny.edu/~weigang/I
mages/20-17_diskdiffusion.jpg 
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QUALITY CONTROL 
 
Performed for each new lot number. See results on next page. 
Control organisms – E.coli ATCC 25922 and P. aeruginosa  ATCC 27853. 
 
TABLE 9: Lot numbers and expiry dates of reagents used for disk diffusion testing. 
 
 LOT NUMBER EXPIRY DATE 
MUELLER HINTON AGAR:   
Greenpoint Nil 21-02-07 
Bio-Rad 2418D 13-04-07 
BioMerieux 807673101 16-01-07 
   
ANTIBIOTIC DISCS:   
Amikacin  05-2009 
Gentamicin 461298 07-2009 
Tobramycin 450224 05-2009 
 
 
REFERENCES: 
 
Performance Standards for Antimicrobial Disk Susceptibility Tests, Approved Standard- 9
th
 edition, 
M2-A9 Vol. 26 No. 1, January 2006, Clinical and Laboratory Standards Institute. 
 
Performance Standards for Antimicrobial Susceptibility Testing; 16
th
 Informational Supplement, M100-
S16, Vol. 26 No.3, January 2006, CLSI. 
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TABLE 9: Results of disk diffusion testing 
 
                                                                                                                                                                              DATA COLLECTION SHEET: DISC DIFFUSION TESTING                                    
                                     GENTAMICIN OVERALL RESULT                         AMIKACIN           OVERALL RESULT                           TOBRAMYCIN OVERALL RESULT
          ISOLATE BIOMERIEUX BIO-RAD GREENPOINT BIOMERIEUX   BIO-RAD GREENPOINT BIOMERIEUX   BIO-RAD GREENPOINT
2 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 19mm 20mm 18mm SENSITIVE (19mm)
3 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 10mm NZ NZ RESISTANT (3mm)
4 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 10mm 10mm 11mm RESISTANT (10mm)
5 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 11mm 11mm 11mm RESISTANT (11mm)
6 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 14mm 14mm 15mm INTERMEDIATE (14mm)
7 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ)
8 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 12mm 13mm 14mm INTERMEDIATE (13mm)
9 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 15mm 15mm 16mm SENSITIVE (15mm)
10 NZ NZ NZ RESISTANT (NZ) 9mm 9mm 8mm RESISTANT (9mm) 13mm 13mm 13mm INTERMEDIATE (13mm)
11 NZ NZ NZ RESISTANT (NZ) 8mm 7mm 8mm RESISTANT (8mm) 13mm 13mm 13mm INTERMEDIATE (13mm)
12 NZ NZ NZ RESISTANT (NZ) 7mm NZ 7mm RESISTANT (5mm) 9mm 8mm 9mm RESISTANT (9mm)
13 NZ NZ NZ RESISTANT (NZ) 8mm 8mm 9mm RESISTANT (8mm) 11mm 11mm 13mm RESISTANT (11mm)
14 NZ NZ NZ RESISTANT (NZ) 8mm 7mm 7mm RESISTANT (7mm) 14mm 15mm 14mm INTERMEDIATE (14mm)
15 NZ NZ NZ RESISTANT (NZ) 9mm 8mm 12mm RESISTANT (10mm) 15mm 15mm 15mm SENSITIVE (15mm)
16 21mm 22mm 22mm SENSITIVE (22mm) 8mm NZ NZ RESISTANT (3mm) 22mm 25mm 21mm SENSITIVE (23mm)
17 NZ NZ NZ RESISTANT (NZ) 9mm 8mm 9mm RESISTANT (9mm) 13mm 13mm 13mm INTERMEDIATE (13mm)
18 NZ NZ NZ RESISTANT (NZ) 8mm NZ 9mm RESISTANT (6mm) 13mm 12mm 13mm INTERMEDIATE (13mm)
20 NZ NZ NZ RESISTANT (NZ) 8mm NZ 8mm RESISTANT (5mm) 15mm 15mm 15mm SENSITIVE (15mm)
21 21mm 22mm 21mm SENSITIVE (21mm) 10mm 9mm 9mm RESISTANT (9mm) 23mm 25mm 24mm SENSITIVE (15mm)
22 NZ NZ 11mm RESISTANT (4mm) 8mm NZ 8mm RESISTANT (5mm) 15mm 16mm 16mm SENSITIVE (16mm)
23 8mm 8mm 9mm RESISTANT (8mm) 8mm 8mm 9mm RESISTANT (8mm) 19mm 22mm 21mm SENSITIVE (21mm)
24 NZ NZ NZ RESISTANT (NZ) 20mm 22mm 24mm SENSITIVE (22mm) 20mm 22mm 23mm SENSITIVE (22mm)
25 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 20mm 22mm 21mm SENSITIVE (21mm)
26 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (0mm)
27 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (0mm)
28 22mm 22mm 21mm SENSITIVE (22mm) NZ NZ NZ RESISTANT (NZ) 23mm 24mm 21mm SENSITIVE (23mm)
29 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 14mm 15mm 14mm INTERMEDIATE (14mm)
30 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 20mm 20mm 21mm SENSITIVE (20mm)
31 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 12mm 11mm 12mm RESISTANT (12mm)
32 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 15mm 18mm 18mm SENSITIVE (17mm)
33 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 10mm 10mm 10mm RESISTANT (10mm)
34 21mm 22mm 21mm SENSITIVE (22mm) 20mm 23mm 23mm SENSITIVE (22mm) 22mm 24mm 22mm SENSITIVE (23mm)
35 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 20mm 22mm 20mm SENSITIVE (21mm)
36 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 13mm 13mm 13mm INTERMEDIATE (13mm)
37 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 20mm 22mm 20mm SENSITIVE (21mm)
38 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (0mm)
39 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 14mm 15mm 16mm SENSITIVE (15mm)
40 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) NZ 13mm NZ RESISTANT (4mm)
41 NZ NZ NZ RESISTANT (NZ) 20mm 21mm 22mm SENSITIVE (21mm) 20mm 22mm 21mm SENSITIVE (21mm)
42 NZ NZ NZ RESISTANT (NZ) NZ NZ NZ RESISTANT (NZ) 14mm 14mm 14mm INTERMEDIATE (14mm)
QC: E.coli 21mm 22mm 20mm IN RANGE 22mm 22mm 21mm SENSITIVE (22mm) 21mm 22mm 20mm SENSITIVE (21mm)
QC: P.aeruginosa 19mm 18mm 20mm IN RANGE 21mm 22mm 24mm SENSITIVE (22mm) 24mm 24mm 25mm SENSITIVE (24mm)
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SOP 3: Epsilometric tests (E-Tests)  
 
MATERIALS:        0.85 % saline 
                              Sterile swabs 
                              Etest strips – gentamicin, amikacin, tobramycin 
                              Mueller-Hinton agar ( depth 4mm) from 3 different suppliers 
                         
 
METHOD:   
1. Remove Etest package from freezer (-20 degrees Celsius) and allow the strips to reach room 
temperature for approximately 30 minutes. 
2. Homogenize individual viable colonies from a 24hr agar plate in saline. 
3. Adjust the turbidity to 0.5 McFarland. 
4. Ensure agar surface is dry before inoculation. Dip a swab in the inoculum, remove excess fluid 
and swab the entire agar surface evenly in 3 directions. 
5. Allow the agar surface to dry for 10-15 minutes on the bench. 
6. Place the Etest strips to the agar surface with a sterile forceps. Once the strip is on the agar, do 
not move it. 
7. Incubate the plate at 35 degrees Celsius under aerobic conditions for 24 hrs. 
 
READING AND INTERPRETATION: 
1. Read plates after 24hrs incubation only if sufficient growth is seen and the inhibition ellipse is 
visible. 
2. Read the MIC where the ellipse intersects the scale. 
3. Read the endpoint at complete inhibition of all growth including hazes and isolated colonies. 
 
 
 
 
 
 
 
FIGURE 3: Example of an Etest.  
 
 
Downloaded from: www.uniklinik-
ulm.de/uploads/pics/etest11.jpg 
 
 
 
 
 
 
 
 
 
 
QUALITY CONTROL  
Performed once (as per manufacturer’s instructions) for each lot number of  Etests used. 
  
Control organisms – E.coli ATCC 25922 and P. aeruginosa  ATCC 27853. 
 
Gentamicin Etest Lot No BG 2559 Expiry 2011/09 
Amikacin Etests Lot BG 1765 Expiry 2011/03 
Tobramycin Etest Lot BG 2671 Expiry 2011/03 
 
REFERENCES 
Etest Technical Guide 3B, AB BIODISK 
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Etest Application Sheet, EAS 004, AB BIODISK, 2004 
TABLE 10: Epsilometric susceptibility test results 
 
                                                                                                                     DATA COLLECTION SHEET: EPSILOMETRIC TESTING (ETESTS)
                            GENTAMICIN OVERALL RESULT                 AMIKACIN OVERALL RESULT                    TOBRAMYCIN OVERALL RESULT
ISOLATE BIOMERIEUX BIO-RAD GREENPOINT BIOMERIEUX BIO-RAD GREENPOINT BIOMERIEUX BIO-RAD GREENPOINT
2 32 32 32 RESISTANT (32) 128               >256 128 RESISTANT 2             16(12)             2 (1.5) SENSITIVE (2)
3               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256) 24 32            64 (48) RESISTANT
4               >256               >256               >256 RESISTANT (>256) 256               >256         256 (192) RESISTANT (>256)             16(12) 16             16(12) RESISTANT (16)
5               >256               >256               >256 RESISTANT (>256) 128         256 (192) 128 RESISTANT 8             16(12) 8 INTERMEDIATE (8)
6               >256               >256               >256 RESISTANT (>256)         256 (192) 256 128 RESISTANT 4 4 4 SENSITIVE (4)
7               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256)          256(192) 256 256 RESISTANT (256)
8               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256)                8 (6) 8                8 (6) INTERMEDIATE (8)
9               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256)                8 (6) 8                8 (6) INTERMEDIATE (8)
10               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256) 16             16(12) 16 RESISTANT (16)
11               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256)            16 (12)             16(12)             16(12) RESISTANT (16)
12               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256) 32 32 32 RESISTANT (32)
13               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256) 32 16            64 (48) RESISTANT
14               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256)                8 (6) 8 8 INTERMEDIATE (8)
15               >256               >256               >256 RESISTANT (>256) 64           128 (96) 64 RESISTANT                8 (6) 8 8 INTERMEDIATE (8)
16 2 2                4 (3) SENSITIVE (3)               >256               >256               >256 RESISTANT (>256)             2 (1.5)             2 (1.5)             2 (1.5) SENSITIVE (2)
17               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256) 16 16            16 (12) RESISTANT (16)
18               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256)            16 (12) 16 16 RESISTANT (16)
20               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256) 4                8 (6) 4 SENSITIVE (4)
21 2 2 2 SENSITIVE (2) 64           128 (96) 64 RESISTANT             2 (1.5)             2 (1.5)             2 (1.5) SENSITIVE (2)
22               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256)                8 (6)                8 (6) 4 INTERMEDIATE (8)
23 32 32 32 RESISTANT (32)               >256               >256               >256 RESISTANT (>256) 2 2 2 SENSITIVE (2)
24 64           128 (96) 16 RESISTANT 4 4             2 (1.5) SENSITIVE 2 2 1 SENSITIVE
25 32 32 32 RESISTANT (32)               >256 256 256 RESISTANT (>256) 2 2 2 SENSITIVE (2)
26               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256) 32 64            64 (48) RESISTANT
27               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256) 64 64 64 RESISTANT (64)
28             2 (1.5) 2             2 (1.5) SENSITIVE (2) 128 128 64 RESISTANT 1           1 (0.75) 1 SENSITIVE
29               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256)                8 (6) 8 8 INTERMEDIATE (8)
30            64 (48) 64 32 RESISTANT 128 128 128 RESISTANT (128) 2 2 2 SENSITIVE (2)
31               >256               >256               >256 RESISTANT (>256) 128 128 128 RESISTANT (128) 16 16            16 (12) RESISTANT (16)
32 256 256 256 RESISTANT (256)               >256               >256               >256 RESISTANT (>256) 4 4 4 SENSITIVE
33               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256) 16 16 16 RESISTANT (16)
34             2 (1.5) 1 1 SENSITIVE                 4(3) 2                 4(3) SENSITIVE             2 (1.5) 1 1 SENSITIVE
35 32 32            16 (12) RESISTANT 128 128 64 RESISTANT             2 (1.5)             2 (1.5)             2 (1.5) SENSITIVE (2)
36               >256               >256               >256 RESISTANT (>256) 128 128 128 RESISTANT (128) 8 8 8 INTERMEDIATE (8)
37 32 32 32 RESISTANT (32)           128 (96) 128 64 RESISTANT             2 (1.5)             2 (1.5)             2 (1.5) SENSITIVE (2)
38 256               >256               >256 RESISTANT (>256) 128 128 128 RESISTANT (128) 32            64 (48) 32 RESISTANT
39               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256) 4                8 (6)                8 (6) INTERMEDIATE 
40               >256               >256               >256 RESISTANT (>256) 128           128 (96) 128 RESISTANT (128)                8 (6) 8                8 (6) INTERMEDIATE (8)
41 32 32 32 RESISTANT (32)                4 (3) 4                 4(3) SENSITIVE 2 2 2 SENSITIVE
42               >256               >256               >256 RESISTANT (>256)               >256               >256               >256 RESISTANT (>256)                8 (6) 8                8 (6) INTERMEDIATE (8)
QC: E.coli 1 1 1 IN RANGE 2 2 1 IN RANGE 1 1 0.5 IN RANGE
QC: P.aeruginosa 2 4 2 IN RANGE 4 4 2 IN RANGE 1 1 0.5 IN RANGE
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4.4 AGAR DILUTION RESULTS 
 
Agar dilution susceptibility testing was performed and analysed used CLSI criteria by the R&D 
Division, Biomerieux, France. The testing was done in duplicate by 2 different scientists. 
 
TABLE 11: Agar dilution susceptibility test results 
ISOLATE TECH 1 TECH 2 RESULT
2 <=0.5 <=0.5 S
3 16 16 R 
4 8 8 I
5 8 8 I
6 2 2 S
7 128 128 R
8 4 4 S
9 2 2 S
10 4 4 S
11 4 4 S
12 8 8 I
13 4 4 S
14 4 4 S
15 4 4 S
16 <=0.5 <=0.5 S
17 2 2 S
18 4 4 S
20 2 2 S
21 <=0.5 <=0.5 S
22 2 2 S
23 <=0.5 <=0.5 S
24 <=0.5 <=0.5 S
25 NT NT NT
26 2 2 S
27 32 32 R
28 <=0.5 <=0.5 S
29 2 2 S
30 <=0.5 <=0.5 S
31 16 16 R
32 2 2 S
33 4 8 I
34 <=0.5 <=0.5 S
35 <=0.5 <=0.5 S
36 16 16 R
37 <=0.5 <=0.5 S
38 16 16 R
39 2 2 S
40 4 4 S
41 <=0.5 <=0.5 S
42 4 4 S
ATCC 25922 <=0.5 <=0.5
ATCC 27853 <=0.5 <=0.5
ATCC 25923 <=0.5 <=0.5
ATCC 29213 <=0.5 <=0.5
ATCC 35218 <=0.5 <=0.5
ATCC 29212 4 4  
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4.5 BROTH MICRODILUTION RESULTS 
 
Broth microdilution was performed according to CLSI guidelines by the R&D Division, Biomerieux, 
France. The testing was done in duplicate by 2 different scientists. 
 
TABLE 12 : Results of Broth Microdilution Testing 
                                                  BROTH MICRODILUTION
                      GENTAMICIN                         AMIKACIN                TOBRAMYCIN aacC2a
 ISOLATE CCH IC RESULT CCH CD RESULT CCH VM RESULT
2 64 64 R 256 256 R 1 1 S Absent
3         >256         >256 R 256 256 R 128 256 R Absent
4         >256         >256 R         >256         >256 R 64 256 R Absent
5         >256         >256 R 128 256 R 32 32 R Present
6         >256         >256 R         >256         >256 R 8 32 R Present
7         >256         >256 R         >256         >256 R         >256         >256 R Absent
8         >256         >256 R 256         >256 R 8 8 I Present
9         >256         >256 R 128         >256 R 4 8 I Present
10         >256         >256 R 256 256 R 32 64 R Present
11         >256         >256 R         >256         >256 R 32 32 R Absent
12         >256         >256 R         >256         >256 R 32 32 R Present
13         >256         >256 R 128 128 R 32 32 R Present
14         >256         >256 R 256 256 R 8 8 I Present
15         >256         >256 R 128 256 R 8 8 I Present
16 1 1 S         >256         >256 R 1 1 S Absent
17         >256         >256 R 128 256 R 16 16 R Present
18         >256         >256 R 128         >256 R 16 128 R Present
20         >256         >256 R 128 256 R 4 8 I Present
21 1 1 S 64 128 R 0.5 1 S Absent
22         >256         >256 R         >256         >256 R 8 16 R Present
23         >256         >256 R 256 256 R 8 16 R Absent
24         >256         >256 R 2 8 S 2 2 S Absent
25            NT            NT            NT            NT            NT            NT            NT            NT            NT           NT
26         >256         >256 R 2 4 S 4 8 I Present
27         >256         >256 R         >256         >256 R 128 256 R Absent
28 1 1 S 256 256 R 1 1 S Present
29         >256         >256 R 256         >256 R 4 4 S Absent
30         >256         >256 R 256 256 R 1 1 S Absent
31         >256         >256 R 128         >256 R 32 256 R Present
32         >256         >256 R 128 256 R 4 8 I Present
33         >256         >256 R 256         >256 R 8 8 I Present
34 1 1 S 2 2 S 1 0.5 S Absent
35 256 256 R 256 256 R 2 2 S Absent
36         >256         >256 R 256 256 R 64 128 R Present
37 32 64 R 256 256 R 1 1 S Absent
38 256 256 R 128 128 R 64 128 R Absent
39         >256         >256 R         >256         >256 R 4 16 R Present
40         >256         >256 R 256         >256 R 16         >256 R Present
41 64 64 R 2 4 S 1 1 S Absent
42         >256         >256 R         >256         >256 R 8 8 I Present
ATCC 25922       <=0.5 ? 0.25-1 2 2 0.5-4       <=0.5       <=0.5 0.25-1
ATCC 27853 1 1 0.5-2 2 2 1.0-4.0       <=0.5       <=0.5 0.25-1
ATCC 25923       <=0.5       <=0.5            NT 1 4 4
ATCC 25213       <=0.5       <=0.5 0.12-1 1 1 1.0-4.0       <=0.5       <=0.5 0.12-1
ATCC 35218       <=0.5 1 2 2 1 1
ATCC 29212 4 4 4.0-16.0 64 64 64-256 4 4 8.0-32.0
 
 
KEY: NT-Not tested, ATCC- American Type Culture Collection, CCH/ IC/CD/VM-different 
scientists who performed testing, R-resistant, I-intermediate, S-susceptible. 
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TABLE 13: Summary of tobramycin susceptibility testing 
 
                           DATA COLLATION : TOBRAMYCIN
SPECIMEN NUMBER DISK DIFFUSION ETEST VITEK 0.6 VITEK 1.0 AGAR DILUTION BROTH MICRODILUTION ERRORS CLONES
2 S S S S S S B
3 R R I R R R MINOR D
4 R I I I I R MINOR C
5 R I I I I R MINOR C
6 I S S S S R VERY MAJOR C
7 R R R R R R D
8 R I S S S I MINOR C
9 I I S S S I MINOR C
10 R R I S S R MINOR C
11 I I S S S R VERY MAJOR C
12 R R I I I R MINOR C
13 R R S S S R VERY MAJOR C
14 I I S S S I MINOR C
15 I I S S S I MINOR C
16 S S S S S S A
17 R R S S S R VERY MAJOR C
18 I R I S S R MINOR C
20 I S S S S I MINOR C
21 S S S S S S A
22 S I S S S R VERY MAJOR C
23 S S S S S R VERY MAJOR B
24 S S S S S S C
25 S S S S NT NT NT
26 R R R R S I MINOR C
27 R R R R R R D
28 S S S S S S A
29 I I S S S S C
30 S S S S S S A
31 R R S S R R VERY MAJOR C
32 S S S S S I MINOR C
33 R I S S I I MINOR C
34 S S S S S S A
35 S S S S S S B
36 I I S S R R VERY MAJOR C
37 S S S S S S B
38 R R R R R R A
39 S I S S S R VERY MAJOR C
40 R I S S S R VERY MAJOR C
41 S S S S S S C
42 I I S S S I MINOR C  
 
KEY: R- resistant, I- intermediate, S- susceptible. 
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GENETIC ANALYSIS OF STRAINS 
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PCR for aac(3)-IIa gene: 
 
DNA extraction was performed using the NucliSens Lysis Buffer (bioMerieux), NucliSens Magnetic 
Extraction Reagents (bioMerieux) and EasyMag (bioMerieux) as per manufacturer’s instructions. 
 
Example of nucleic acid extraction worksheet used in the study                       
 
 
EXTRACTION WORKSHEET NUMBER :                                
 
METHOD OF EXTRACTION : EasyMag® 2.0 (bioMerieux)       DATE :   05/11/2009 
 
BSL CABINET NO : TB Cabinet 2                                           OPERATOR : Mischka 
                                                                                                      
INCUBATOR: N/A                                                                      
 
INSTRUMENT NUMBER : 00897 
 
 
PCR 
TYPE 
STORAGE NO SAMPLE  
TYPE 
VOLUME 
EXTRACTED 
ELUTION  
VOLUMES 
COMMENTS 
    0.010ml 50µl  
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
 
 
TABLE 14: Reagents used for DNA extraction 
 LOT Number Expiry date Manufacturer 
NucliSens® Lysis 
Buffer (2ml) 
09020501 2011-01 bioMerieux 
NucliSens® Magnetic  
Extraction Reagents 
Z011AAIMS 2011-01 bioMerieux 
Extraction Buffer 1 Z011EA 2011-05 bioMerieux 
Extraction Buffer 2 Z010LA 2010-10 bioMerieux 
Elution Buffer Z010GC 2010-07 bioMerieux 
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Following extraction, the quantity and quality of the DNA extracted was assessed using the Nanodrop. 
 
 
ACINETOBACTER SPECTROPHOTOMETRY: 
 
Absorbance measurements were used to assess the quantity and purity of DNA extracted. A ratio of 
>1.8 was accepted as “pure” for DNA. 
 
The Nanodrop® ND-1000  (Nanodrop Technologies, Inc.) spectrophotometer was utilised.  See SOP 
on next page.  
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SOP 4: 
~ 
.no ........ " 
... .. " ... ...... . 
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TABLE 15: Results of photospectrometric measurements using the Nanodrop 
Sample ng/µL A260 A280 260/280 
1 39.92 0.658 0.327 2.01 
2 19.21 0.384 0.199 1.93 
3 28.06 0.561 0.280 2.00 
4 38.20 0.764 0.379 2.02 
5 28.60 0.572 0.285 2.01 
6 29.80 0.596 0.310 1.92 
7 26.61 0.532 0.258 2.06 
8 24.35 0.487 0.207 2.36 
9 43.05 0.861 0.473 1.82 
10 32.65 0.653 0.268 2.43 
11 38.87 0.777 0.381 2.04 
12 45.55 0.911 0.439 2.08 
13 18.38 0.368 0.195 1.89 
14 55.65 1.113 0.541 2.06 
15 22.12 0.442 0.218 2.03 
16 31.21 0.624 0.320 1.95 
17 17.51 0.350 0.200 1.75 
18 35.23 0.705 0.366 1.92 
19 49.42 0.988 0.485 2.04 
NEG1(Extraction Control) 2.07 0.041 0.056 0.74 
20 39.49 0.790 0.381 2.07 
21 50.27 1.005 0,504 1.99 
22 47.85 0.957 0.455 2.10 
23 29.97 0.599 0.282 2.12 
24 35.01 0.700 0.345 2.03 
25 42.20 0.844 0.414 2.04 
26 32.77 0.655 0.330 1.98 
27 28.91 0.578 0.288 2.01 
28 51.39 1.028 0.478 2.15 
29 30.64 0.613 0.286 2.14 
30 8.33 0.167 0.089 1.87 
31 51.60 1.032 0.493 2.09 
32 50.29 1.006 0.474 2.12 
33 51.98 1.040 0.496 2.10 
34 13.26 0.265 0.131 2.02 
35 64.14 1.283 0.618 2.07 
36 67.88 1.358 0.633 1.95 
37 78.78 1.576 0.742 2.12 
38 55.69 1.114 0.532 2.10 
39 21.10 0.422 0.203 2.08 
NEG2(Extraction Control) 2.40 0.048 0.038 1.26 
MOS-1(Positive Control) 1140.58 22.812 10.773 2.12 
Positive control  1:100 dilution 31.71 0.634 0.350 1.81 
MOS-2(Negative Control) 85.25 1.705 0.845 2.02 
 
 
For a PCR product between 100-200bp long, a minimum 1-3ng of DNA is required. Therefore to 
detect a PCR product of 786bp, a minimum of 4-12ng of DNA will be required. The nanodrop 
confirmed the quantity of DNA extracted which ranged from 8.33 to 78.78 (average 62.2ng). 
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POLYMERASE CHAIN REACTION FOR aac(3)-IIa 
 
MASTERMIX:  
 
 
TABLE 16: Contents of mastermix 
Per reaction  
H2O 23.5 µL 
Buffer 10    µL 
MgCl2 (25mM)   6    µL 
dNTPs (2.5 mM of each dNTP)   4   µL  
Forward Primer (10picomoles/ µL)   2   µL 
Reverse Primer (10picomoles/ µL)   2   µL 
Taq polymerase (5U/ µL) 0.5  µL 
Template  2     µL 
Total 50   µL 
 
 
 
TABLE 17: Details of reagents used 
REAGENTS LOT NO EXPIRY DATE MANUFACTURER 
GoTaq® Flexi DNA 
Polymerase 
#25803910 17/06/2010 Promega Corporation 
Magnesium chloride #25803910 17/06/2010 Promega Corporation 
Molecular weight 
marker(1kb Plus DNA 
Ladder) 1µg/µL 
Cat No 10787-018  e-invitrogen 
Forward and Reverse 
Primers 
  Obtained from 
Tsungai Jongwe, 
Division of Medical 
Microbiology. 
 
 
 
TABLE 18: Details of equipment used 
EQUIPMENT MANUFACTURER 
Nanodrop ND 1000 
spectrophotometer 
NanoDrop 
Technologies, Inc. 
Thermocycler 4 
GeneAmp PCR 
System 9700 
AB Applied 
Biosystems 
 
Cycling conditions: 
95(5’); 35x: 95(1’), 51(45”), 72(1’); 72(5’) 
 
A 2% agarose gel was run at 110V for 1 hour. 
 
Expected product size is 786kb. 
 
Controls:  
MOS-1 POSITIVE CONTROL 
MOS-2 NEGATIVE CONTROL 
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TABLE 19: Results of PCR for aac(3)-IIa 
LANE NO  SPECIMEN NO. RESULT 
1 MWM  
2 Isolate 38 Absent 
3 Isolate 21 Absent 
4 Isolate 28 Present 
5 Isolate 16 Absent 
6 Isolate 34 Absent 
7 Isolate 30 Absent 
8 Isolate 37 Absent 
9 Isolate 23 Absent 
10 Isolate 35 Absent 
11 Isolate 2 Absent 
12 POSITIVE CONTROL Present 
13 NEGATIVE CONTROL Absent 
14 EXTRACTION CONTROL Absent 
15 BLANK (Water) Absent 
   
   
1 MWM  
2 Isolate 17 Present 
3 Isolate 32 Present 
4 Isolate 22 Present 
5 Isolate 20 Present 
6 Isolate 9 Present 
7 Isolate 31 Present 
8 Isolate 10 Present 
9 Isolate 29 Absent 
10 Isolate 33 Present 
11 Isolate 11 Absent 
12 POSITIVE CONTROL Present 
13 NEGATIVE CONTROL Absent 
14 EXTRACTION CONTROL Absent 
15 BLANK (Water) Absent 
   
   
1 MWM  
2 Isolate 4 Absent 
3 Isolate 39 Present 
4 Isolate 36 Present 
5 Isolate 8 Present 
6 Isolate 5 Present 
7 Isolate 6 Present 
8 Isolate 42 Present 
9 Isolate 18 Present 
10 Isolate 14 Present 
11 Isolate 13 Present 
12 POSITIVE CONTROL Present 
13 NEGATIVE CONTROL Absent 
14 EXTRACTION CONTROL Absent 
15 BLANK (Water) Absent 
   
   
1 MWM  
2 Isolate 40 Present 
3 Isolate 26 Present 
4 Isolate 12 Present 
5 Isolate 15 Present 
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6 Isolate 41 Absent 
7 Isolate 24 Absent 
8 Isolate 3 Absent 
9 Isolate 27 Absent 
10 Isolate 7 Absent 
11   
12 POSITIVE CONTROL Present 
13 NEGATIVE CONTROL Absent 
14 WATER Absent 
15   
 
REPEAT PCR OF NEGATIVES 
 
1 MWM  
2   
3 1  
4 2  
5 3  
6 4  
7 5  
8 6  
9 7  
10 8  
11 9  
12 10  
13 POSITIVE CONTROL  
14 NEGATIVE CONTROL  
15 WATER  
   
1 MWM  
2   
3 18  
4 20  
5 35  
6 36  
7 37  
8 38  
9 39  
10 POSITIVE CONTROL  
11 NEGATIVE CONTROL  
12 WATER  
13   
14   
15   
 
2% gel run at 110V for 1 hour, 1kb ladder used. 
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FIGURE 4: GEL 1  
Lane 1: Molecular weight mark, Lanes 2-11: Specimens 1-10, Lane 12: Positive control, Lane 
13: Negative control, Lane 14: Extraction control, Lane 15: Blank (water). 
 
 
 
 
 
FIGURE 5: GEL 2  
Lane 1: Molecular weight mark, Lanes 2-11: Specimens 11-20, Lane 12: Positive control, Lane 
13: Negative control, Lane 14: Extraction control, Lane 15: Blank (water). 
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FIGURE 6:  GEL 3  
Lane 1: Molecular weight mark, Lanes 2-11: Specimens 21-30, Lane 12: Positive control, Lane 
13: Negative control, Lane 14: Extraction control, Lane 15: Blank (water).  
 
 
Figure 7: GEL 4  
Lane 1: Molecular weight mark, Lanes 2-9: Specimens 31-39, Lane 11: Positive control, Lane 
12: Negative control, Lane 13: Extraction control, Lane 14: Blank (water). 
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FIGURE 9: REPEAT GEL 1  
Lane 1: Molecular weight mark, Lanes 2-11: Specimens 1-10, Lane 12: Positive control, Lane 
13- Negative control, Lane 14- Extraction control, Lane 15- Blank (water). 
 
 
 
 
Figure 10: REPEAT GEL 2  
Lane 1: Molecular weight mark, Lanes 2-8: Specimens 18, 20, 35-39, Lane 9: Positive control, 
Lane 10: Negative control, Lane 11: Extraction control, Lane 12: Blank. 
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SOP 5: 16S rRNA PCR (Adapted from NHLS SOP MIC0742) PCR Amplification and DNA 
Sequencing of 16srRNA and ITS2 r DNA for Fungal identification 
 
PRINCIPLE 
  
16S rRNA:  
 
All bacteria have genes encoding the RNA for the 16S subunit of the ribosome. These genes are 
highly conserved (i.e. there are areas of the gene that do not differ between different genera of 
bacteria), allowing one set of primers to amplify DNA from a wide range of bacterial species. 
However, some differences between species do exist, so analysis of DNA sequence data from these 
genes can allow one to identify the organism from which the DNA was amplified. 
 
16s rRNA Primers: 
 
BAKF – 5’ – AGA GTT TGA TCC TGG CTC AG  3’  
BAKR – 3’ – AAG GAG GTG ATC CAG CCG CA – 5’ 
 
(Ref: Edwards U et al. 1989. Isolation of a direct complete nucleotide determination of entire genes. 
Characterisation of a gene coding for 16S ribosomal RNA. Nucleic Acids Res. 17: 7843 – 7853) 
 
PROCEDURE: 
Use 5µl of extracted DNA for your PCR reaction 
 
PCR Reaction Mixture (Mastermix) 16s RNA: 
 
PCR reaction mix for 10 samples 
 
dNTPs 4x1µl each  4 
Taq polymerase 3 
MgCl 30 
Buffer  50 
Water 293 
Total volume 380 
Volume for each reaction 38 µl 
 
 
Add 1µl of each forward (20pmol/µl) and reverse (20pmol/µl) primer from the working stock to each 
mastermix. 
 
Use E. coli genomic DNA as a positive control, and always include both a blank control, and a water 
(negative) control. 
 
 
PCR assay: 
 
The conditions are programmed into the thermocycler – Programme “16s rRNA PCR” 
 
The conditions are:   
94°C for 2 minutes 
94°C for 20 seconds; 47°C for 30 seconds, 72°C for 45 seconds – for 35 cycles 
72°C for 7 minutes 
Hold at 4°C 
 
Detection of PCR product: 
 
1. After completion of the PCR assay run 10µl of product on a 2% agarose gel. 
2. Set the powerpack at 90 volts and run for approximately 30 to 40 minutes. 
3. Once the products have run sufficiently visualise the products in the UV transilluminator.  
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4. Place the gel on the glass surface of the transilluminator and take a photograph of the gel using the 
Uvitec Gel Documentation System (SOP CHE0627). 
5. Capture the image and save in the S drive/laboratories/microbiology/common/read and write 
only/gel images/then the name and date the gel photo was taken. 
 
 
 
 
FIGURE 11: 
Lane 1: MWM, Lanes 2-17: Isolates (1,2,4,5,6,7,8,9,10,18,20,35,36,37,38,39)with negative aac(3)-
IIa PCR,  N: Negative control, P: Positive Control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  MWM    2       3       4       5       6      7       8       9      10     11     12               13    14      15     16     17     18     19 
             1       2        4       5       6            7     8        9     10      18      20           35    36     37   38     39        N        P 
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SEQUENCING SOP 6: 
 
 
 
 
 
•• 
CD' ,-,' 
'£::, 
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STANDARD OPERA TINa PROCEDURE 
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FORWARD PRIMER SEQUENCE(aacC2a) :  5’-3’ : cgc gga agg caa taa c 
REVERSE PRIMER SEQUENCE(aacC2a) :    5’-3’ : gct tct caa gat agg tg 
 
 
TABLE 20: Nanodrop results of isolates sent for sequencing 
SAMPLE DATE TIME ng/µL A260 A280 260/230 260/230 
1 26/11/09 12h11 60.42 1.208 0.640 1.89 0.41 
3 26/11/09 12h12 138.05 2.761 1.458 1.89 1.25 
11 26/11/09 12h13 141.12 2.822 1.497 1.89 0.81 
Forward 
Primer 
09/11/09 08h54 81.19 1.624 0.741 2.19 2.29 
Reverse 
Primer 
09/11/09 08h56 70.59 1.412 0.818 1.73 2.39 
 
Reaction mixture(per sample) 
 
H2O                 23.5  µL 
Buffer              10.0  µL 
MgCl2                  6   µL 
dNTP                  4   µL 
Forward primer   2   µL 
Reverse primer   2   µL 
Taq polymerase 0.5 µL  
Template             2   µL 
 
Primer             1.0 µL (20pmoles/ µL) 
 
Mix and place in thermocycler. 
 
Program 96° 15”, 30x : (96° 15”, 50° 15”, 60° 4’), 60° 10’.  
 
TABLE 21: Reagents used for PCR  
REAGENT LOT NUMBER DATE MANUFACTURER 
5x Colourless 
GoTaq® Flexi Buffer 
#25803910 17-06-2010 Promega Corporation 
Magnesium chloride 
25mM 
#25803910 17-06-2010 Promega Corporation 
GoTaq® Flexi DNA 
Polymerase 
#25803910 17-06-2010 Promega Corporation 
BigDye Terminator 
v3.1 Ready Reaction 
Cycle sequencing kit 
  AB Biosystems 
 
EQUIPMENT MANUFACTURER 
Thermocycler 9 Hybaid Express 
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FIGURE 12: Check gel of sequencing products 
Lane 1: MWM, Lane 3-: Isolate 38, Lane 5: Isolate 28 , Lane 7- Isolate 17. 
 
Three isolates were selected- 2 isolates with a positive PCR (isolate 17 and 28). Isolate 38 was also 
sequenced as an additional band at approximately 1.6 kb was visible on PCR for aac(3)-IIa. 
 
The sequencing was performed at the DNA Sequencing Facility at the University of Stellenbosch 
using ABI genetic analyzers. The BLAST (Basic Local Alignment Search Tool) nucleotide collection 
database was searched using Megablast to find highly similar sequences. The results are shown 
below. 
 
Chromas software was used to evaluate the quality of the sequencing using the chromatogram.  
 
 
 
Figure 13: An example of the chromatogram obtained using Chromas Lite software. 
 
Good chromatograms were obtained for isolates 17 and 38. However, the chromatogram for isolate 
38 revealed evidence of a mixed sample. 
 
 
SEQUENCE OF ISOLATE 38(FORWARD PRIMER) FASTA SEQUENCE:  
 
TTGCAATGCGCTGCATATGYGAGMTGTACCGGTCATAGATCTGATCKCAGTGYTGMSATTGCAC
CTGTGGCGTTTTTTCACCGGATTTACCAMCTACTGCCTCTTCTATTTTGAAAAACKGSGCTTTCAC
CCATCTGATGCTTACAATTCTGGCTATGTCTTACATTGCCGCGRCGAARGCTTTTTGATCTGTTAT
TCTTACTTATGGTTCCTCTTGMCCTGCTGTGAATTTTTGKACCTTGTTTGTTGTGCRTGATTTTTGA
RGGGATTGRATTCSGAATACATACTACTTGYTCASARWGGKCCRCCTTAATCGRAMCKATGARC
CTCCTTGTTTCGTCTGCTTATTTCTGGWACGACTTCTCACCCTTGCCWGCCGCCTTCGATCATTA
CACCATTTATGATTATCTGACTGATTTCTGCCAGCCACGTGWATCACAACATTTTCTAAAGCTTTT
CACTGAATGAATGATTGGMCGTGKWCTGGAKGACACACSCGCMCGKCTTCYARWTGCWGTGW
RMMAKGTATCGTATTRCAARGACKAACCGCTATCKAAAAGATTGTGMTTGTGCTCGCGAKCSACT
TTGGWKGYWGKKYCKGCWKYAYCTTAYTGCAWGWTGAWYACGTGGAYGAAATTCATGTGGAAT
CAGATGAARATCWTSRTACKTTGCTTCGTCCGACTCTGTCTGMTCAAYASATTCRRACGATCAWA
CRWMTSMWGATCTGMATCTGWKACCCCWGAAYWKSWCCCAGAKWWCMATTTTCACGAAKRA
10µL run 
on 2% gel 
Product 
size 786bp 
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GCCAMWGCCGMAMCTGMAGCTGTCCCGMCCTAMRMTRRCWAMCTTTCCAKRGCYWTATTCTT
CGTATGMAWACYGSTRMTCGCRCTGTACSYSAYGCCGGGTWYSCSTCATAMCYGCWKCYMYYS
CCYACTSWKGGACATKWCTAAAYGACGTGMTCGTRCACCKGCTGCTGATCTTCAAMGAATGMY
CATMATKTGKSTKAKATSSARKSCCYGMCWGGGTGGAATRCSTKCCAMCACYMSCAGMAAGACT
WGAAGATCCYWCTGTCAATAGSTASCACTSTGACGATCRTGWTCCGACYYCTGCCCTCTGAAAT
CCGAGAACCGGRCGATACYACGCTWATGCTCTGGAAACTCGYGAATCWCGAACCTATGCCGAT
GAGCTATGAGCCATTCAAGGTTCGAAAKCGYGACTCGTGG 
  
No result was obtain when Isolate 38 was blasted using MegaBlast or . However a result was 
obtained using Blastn (dissimilar). This sequence showed some similarity with the A. baumannii 
dioxygenase. This is an enzyme that is involved in iron binding. However, the association is weak. 
 
 
 
 
SEQUENCE OF ISOLATE 38(REVERSE PRIMER) FASTA SEQUENCE: 
 
TTTCGYGGAAGGCAATAACACAKACATAACTGGAATAAAGAATAGAACCAGTACAGTACCAAACA
KTRCGCCGCCTAAAATASTAATACCAATTTYTTGGSGGSTCACCGCRCCAGSGCCTTGGGCAAAT
ACAAGTGGAATCACACSKGCASCAAAGGCTAAAGAAGTCATTAAAATSGGTCTTAAACGCAAGCT
CGCACSTTATAAAGCGGCCKGAATAGCATTCTTTCCTTTSTCTTGGGSTAAKGCAGCAAACTCAA
CAATTAAAATTGSGTTKWTGCATGACAATMCAATCGTGGTTAGAAGTGCAATTCGCGGAAGGCAA
TAACACCCAGCTGMCACRCAGAMCAGMACAYAATWTT. 
 
When this sequence was blasted using Blastn, a weak similarity was found with the RND multidrug 
efflux pump of A. calcoaceticus PKEA-2. The association was too weak to draw any further 
conclusions. 
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SEQUENCE OF ISOLATE 28( FORWARD PRIMER) FASTA SEQUENCE : 
 
 
TAGYSASSTCGGGRGTCAACCGGTGACCTGTTGATGGTGCATGCCTCACTTAAAGCGATTGGTC
CGGTCGAAGGAGGAGCGGAGACGGTCGTTGCCGCGTTACGCTCCGCGGTTGGGCCGACTGGC
ACTGTGATGGGATACGCGTCGTGGGACCGATCACCCTACGAGGAGACTCTGAATGGCGCTCGG
TTGGATGACAAAGCCCGCCGTACCTGGCCGCCGTTCGATCCCGCAACGGCCGGGACTTACCGT
GGGTTCGGCCTGCTGAATCAATTTCTGGTTCAAGCCCCCGGCGCGCGGCGCAGCGCGCACCCC
GATGCATCGATGGTCGCGGTTGGTCCGCTAGCTGAAACGCTGACGGAGCCTCACGAACTCGGT
CACGCCTTGGGGAAAGGGTCGCCCGTCGAGCGGTTCGTCCGCCTTGGCGGGAAGGCCCTGCT
GTTGGGTGCGCCGCTAAACTCCGTTACCGCATTGCACTACGCCGAGGCGGTTGCGGATATCCC
CAACAAACGATGGGTGACGTATGAGATGCCGATGCTTGGAAGAAACGGTGAAGTCGCCTGGAAA
ACGGCATCAGAATACGATTCAAACGGCATTCTCGATTGCTTTGCTATCGAAGGAAAGCCGGATGC
GGTCGAAACTATAGCAAATGCTTACGTGAAGCTCGGTCGCCATCGAGAAGGTGTCGTGGGCTTT
GCTCAGTGCTACCTGTTCGACGCGCAGGACATCGTGACGTTCGGCGTCACCTATTTTKGAGAAG
C 
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SEQUENCE OF ISOLATE 28(REVERSE PRIMER) FASTA SEQUENCE : 
 
GCCSGSYKTWKAWCTGCGCGTCGACAGGTAGCACTGAGCAAAGCCCACGACACCTTCTCGATG
GCGACCGAGCTTCACGTAAGCATTTGCTATAGTTTCGACCGCATCCGGCTTTCCTTCGATAGCAA
AGCAATCGAGAATGCCGTTTGAATCGTATTCTGATGCCGTTTTCCAGGCGACTTCACCGTTTCTT
CCAAGCATCGGCATCTCATACGTCACCCATCGTTTGTTGGGGATATCCGCAACCGCCTCGGCGT
AGTGCAATGCGGTAACGGAGTTTAGCGGCGCACCCAACAGCAGGGCCTTCCCGCCAAGGCGGA
CGAACCGCTCGACGGGCGACCCTTTCCCCAAGGCGTGACCGAGTTCGTGAGGCTCCGTCAGCG
TTTCAGCTAGCGGACCAACCGCGACCATCGATGCATCGGGGTGCGCGCTGCGCCGCGCGCCG
GGGGCTTGAACCAGAAATTGATTCAGCAGGCCGAACCCACGGTAAGTCCCGGCCGTTGCGGGA
TCGAACGGCGGCCAGGTACGGCGGGCTTTGTCATCCAACCGAGCGCCATTCAGAGTCTCCTCG
TAGGGTGATCGGTCCCACGACGCGTATCCCATCACAGTGCCAGTCGGCCCAACCGCGGAGCGT
AACGCGGCAACGACCGTCTCCGCTCCTCCTTCGACCGGACCAATCGCTTTAAGTGAGGCATGCA
CCATCAACAGGTCACCGGTTTGGACTCCGAGTTTTCGAATTGCCTCCGTTATGCCCTTCCGCGA 
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SEQUENCE OF ISOLATE 17( FORWARD PRIMER ) FASTA SEQUENCE: 
 
TWKYGRCYTCGGGAGTCAAACCGGTGACCTGTTGATGGTGCATGCCTCACTTAAAGCGATTGGT
CCGGTCGAAGGAGGAGCGGAGACGGTCGTTGCCGCGTTACGCTCCGCGGTTGGGCCGACTGG
CACTGTGATGGGATACGCGTCGTGGGACCGATCACCCTACGAGGAGACTCTGAATGGCGCTCG
GTTGGATGACAAAGCCCGCCGTACCTGGCCGCCGTTCGATCCCGCAACGGCCGGGACTTACCG
TGGGTTCGGCCTGCTGAATCAATTTCTGGTTCAAGCCCCCGGCGCGCGGCGCAGCGCGCACCC
CGATGCATCGATGGTCGCGGTTGGTCCGCTAGCTGAAACGCTGACGGAGCCTCACGAACTCGG
TCACGCCTTGGGGAAAGGGTCGCCCGTCGAGCGGTTCGTCCGCCTTGGCGGGAAGGCCCTGCT
GTTGGGTGCGCCGCTAAACTCCGTTACCGCATTGCACTACGCCGAGGCGGTTGCGGATATCCC
CAACAAACGATGGGTGACGTATGAGATGCCGATGCTTGGAAGAAACGGTGAAGTCGCCTGGAAA
ACGGCATCAGAATACGATTCAAACGGCATTCTCGATTGCTTTGCTATCGAAGGAAAGCCGGATGC
GGTCGAAACTATAGCAAATGCTTACGTGAAGCTCGGTCGCCATCGAGAAGGTGTCGTGGGCTTT
GCTCAGTGCTACCTGTTCGACGCGCAGGACATCGTGACGTTCGGCGTCACCTATYTTKGAGAAA
GMAA. 
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SEQUENCE OF ISOLATE 17( REVERSE PRIMER) FASTA SEQUENCE: 
 
GGCSGATGTAWWAWCTGCGCGTCGACAGGTAGCACTGAGCAAAGCCCACGACACCTTCTCGAT
GGCGACCGAGCTTCACGTAAGCATTTGCTATAGTTTCGACCGCATCCGGCTTTCCTTCGATAGCA
AAGCAATCGAGAATGCCGTTTGAATCGTATTCTGATGCCGTTTTCCAGGCGACTTCACCGTTTCT
TCCAAGCATCGGCATCTCATACGTCACCCATCGTTTGTTGGGGATATCCGCAACCGCCTCGGCG
TAGTGCAATGCGGTAACGGAGTTTAGCGGCGCACCCAACAGCAGGGCCTTCCCGCCAAGGCGG
ACGAACCGCTCGACGGGCGACCCTTTCCCCAAGGCGTGACCGAGTTCGTGAGGCTCCGTCAGC
GTTTCAGCTAGCGGACCAACCGCGACCATCGATGCATCGGGGTGCGCGCTGCGCCGCGCGCC
GGGGGCTTGAACCAGAAATTGATTCAGCAGGCCGAACCCACGGTAAGTCCCGGCCGTTGCGGG
ATCGAACGGCGGCCAGGTACGGCGGGCTTTGTCATCCAACCGAGCGCCATTCAGAGTCTCCTC
GTAGGGTGATCGGTCCCACGACGCGTATCCCATCACAGTGCCAGTCGGCCCAACCGCGGAGCG
TAACGCGGCAACGACCGTCTCCGCTCCTCCTTCGACCGGACCAATCGCTTTAAGTGAGGCATGC
ACCATCAACAGGTCACCGGTTTGGACTCCGAGTTTTCGAATTGCCTCCGTTATGCCCYTTCCGCG
A 
 
 
 
These sequences are identical to the aac(3)-IIa gene. The alignment with the original sequence is 
shown on the next page. 
 
 
 
REFERENCES: 
1. Zhang, Z., S. Schwartz, L. Wagner, and W. Miller. 2000. A greedy algorithm for aligning 
DNA sequences. J Comput Bid. 7 (1-2): 203-214. 
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MOLECULAR EPIDEMIOLOGY 
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PULSED FIELD GEL ELECTROPHORESIS OF Acinetobacter baumannii strains 
(Adapted from Jacobson, R. Association of IS1133 with an aminoglycoside resistance 
gene,aacC2a, in Acinetobacter baumannii isolates. August 2007.) 
 
STANDARD OPERATING PROCEDURE: 
 
PLUG PREPARATION 
 
1. A bacterial suspension (OD540 1.8-2.0) should be prepared in cell suspension buffer (100mM Tris, 
100mM EDTA, pH 8.0). The bacterial cells were obtained from a single colony plate that had been 
streaked out on 2% horse blood agar after 24 hour incubation at 37°C. 
2. The suspension should be incubated at 55°C for 10min in a water bath. 
3. Twenty-five microlitres of proteinase K (20mg/ml stock solution) and 5µL of lysozyme (100mg/ml) 
should be added to the cell suspension. The mix should be inverted 2-4X. 
4. Five hundred microlitres of 1% Seakem (with 1% SDS) is added to each tube and the suspension 
was gently inverted 10-12X. 
5. The plugs are then cast in plastic moulds and allowed to solidify at room temperature for 5min and 
at 4°C for another 15min. 
 
LYSIS OF CELLS IN PLUGS AND WASHING 
  
6. Five milliliters of cell lysis buffer (50mM Tris, 50 mM EDTA, pH 8.0+1 % sarcosine) together with 
25µL proteinase K (20mg/ml stock solution) and 5µL lysozyme (100mg/ml). 
7. The solution is incubated at 55°C in a shaking incubator for 2 hours. 
8. The plugs are washed 2 X for 15 minutes in 10ml warmed distilled water at 55°C. 
9. The plugs are then washed 3 X for 15 minutes in 10ml warmed TE buffer at 55°C. 
10. The plugs are trimmed to the correct dimensions 2.0mmx 2.5mm 
10. Store the plugs in 10ml fresh TE buffer at 4°C. 
 
RESTRICTION DIGESTION 
 
11. The plug slices are incubated in 179 µL distilled water, 20 µL Buffer A and 1 µL of bovine serum 
albumin (100 µg/ml) at 30°C for 15 minutes. 
12. The buffer is replaced with fresh buffer and BSA, 30 IU Apa1 (restriction endonuclease) is added. 
13. The mix is incubated at 30°C for 2 hours. 
 
ELECTROPHORESIS 
 
14. The plugs are washed with 200 µL 0.5X TBE, then incubated at 4°C for 10 minutes before being 
loaded onto a 1.5%  agarose gel in 0.5X TBE buffer. 
15. The PFGE machine is set at ramped pulses of 5-35s for 23 hours at 200V. 
 
STAIN AND DESTAIN 
 
16. The gel is then stained for 45 min in 0.5µg/ml of ethidium bromide (20 µL of 10mg/ml in 400 ml 
TBE) 
17. The gel is destained in distilled water for an hour to achieve good contrast. 
18. The gel is then photographed using a Fotodyne Inc. UV light box and a Kodak EDAS 290 camera, 
and an analysis using Gel Compare II software Version 4.6 (Applied Maths) was performed. 
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REAGENTS: 
 
 
 
EQUIPMENT: 
 
Equipment  Manufacturer 
PFGE Gene Navigator® Amersham 
Biosciences AB 
Water bath  Memmert 
Fridge  Kelvinator 
Vortex Vortex-Genie 2 Scientific Industries 
Incorporated 
Spectrophotometer General Purpose 
UV/Vis 
spectrophotometer 
DU720 
Beckman-Coulter 
 
 
PREPARATION OF BUFFERS: 
 
Cell Suspension Buffer (100mM Tris, 100mM EDTA, pH 8.0) 
10ml 1M Tris stock, pH 8.0 
20ml 0.5M EDTA stock, pH 8.0 
Dilute to 100ml with sterile ultra pure water 
 
Cell Lysis Buffer (50mM Tris, 50mM EDTA, pH 8.0, 1% Sarcosine) 
12.5 ml 1 M Tris stock 
25 ml 0.5 M EDTA stock 
12.5 ml 10% Sarcosyl (N-Lauryl-Sarcosine) 
Dilute to 250 ml with sterile ultra pure water 
 
TE Buffer 
10mls  1M Tris  1.21g/L 
2 mls 0.5M EDTA 0.37g/L 
pH 8.0 
Dilute up to 1000mls 
 
TBE Buffer 
0.89 M Tris 
 LOT NO Expiry date Manufacturer 
SuRE/Cut Buffer A 14541900 
CAT no 11417959001 
 Roche 
Proteinase K 
(20mg/ml) 
14950500 04-2010 Novagen 
Pulsed Field Gel 
Electrophoresis 
Agarose 
1620137  BioRad 
Lysozyme(100mg/ml)   Roche 
Seakem® Gold 
Agarose 
  Cambrex 
Bovine Serum 
Albumin 
  Roche 
ApaI CAT no 10899208001  Roche 
Blood agar plates Nil 19/01/10 Greenpoint 
Laboratory 
Lambda Ladder PFG 
Marker NO340S 
1100804 04/10 New England Biolabs 
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0.89 M boric acid 
20 mM EDTA 
 
RESULTS 
 
Picture of original gel run (Fotodyne Inc. UV light box and a Kodak EDAS 290 camera) 
 
     1       2      3       4      5       6      7       8      9      10    11    12     13    14 
 
Figure 14: Pulse-field gel electrophoresis on selected isolates. 
 
KEY:Lanes 1,7,13   Molecular weight marker; Lanes 2, 8, 14  Control strain RUH (European 
clone); Lanes 3, 9  MOS-1 strain; Lanes 4, 10  MOS-2 strain; Lanes 5, 11 Representative of 
Cluster C (Isolate 32); Lanes 6, 12 Representative of Cluster A (Isolate 16). 
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Dice (Opt:1.50%) (Tol 1.5%-1.5%) (H>0.0% S>0.0%) [0.0%-100.0%]
PFGE-ApaI
1
0
0
9
5
9
0
8
5
8
0
7
5
7
0
6
5
75
92.3
80
PFGE-ApaI
A.2
RUH 3
MOS-1.2
C.2
MOS-2.2
 
Results obtained using GEL Compare II Version 4.6 (Applied Maths) software are shown in Figure 15. 
 
 
 
 
 
 
 
 
 
 
 
Figure 
15: Pulsed field gel electrophoresis of selected isolates showing their relatedness. 
(KEY: A.2 Isolate 16, RUH 3- European RUH strain, MOS-1.2- MOS-1 strain, C.2- Isolate 32, 
MOS-2.2- MOS-2 strain). 
 
 
STORAGE OF ISOLATES (See Package Insert.) 
 
All isolates were stored on beads (Viabank VIM tubes, Abtek Biologicals Ltd).  
 
 Procedure for storage: 
1. Label the vial. 
2. Make a heavy Inoculation of the organism from a fresh, pure culture. Place into the vial. 
3. Replace cap. 
4. Distribute inoculated broth throughout the beads. 
5. Decant the excess preservative fluid using a sterile pipette. 
6. Replace cap. 
7. Store at -70ºC. 
  
Procedure for recovery of organisms: 
1. Remove a bead with a sterile forceps. 
2. Drop the bead on to the surface of a 2% blood agar plate, and streak across the surface. 
3. Dispose of bead as per laboratory practice in a biohazard container. 
4. Replace the vial in the -70ºC freezer. 
5. Incubate the agar in conditions appropriate for the organism. 
 
Lot GE 03, Expiry date May 2008. 
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RESULTS OF DIVERSILAB TYPING: This part of the experiment was performed by the R&D 
Microbiologie, bioMerieux, La Balme les Grottes. 
 
 
Cluster A
Cluster B
Cluster D
Cluster C
 
Figure 16: Phylogenetic relatedness of the isolates as determined by the Diversilab. 
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KEY:  
 
KEY NO ISOLATE 
1 38 
2 21 
3 28 
4 16 
5 34 
6 30 
7 37 
8 23 
9 35 
10 2 
11 17 
12 32 
13 22 
14 20 
15 9 
16 31 
17 10 
18 29 
19 33 
20 11 
21 4 
22 39 
23 36 
24 8 
25 5 
26 6 
27 8 
28 42 
29 18 
30 14 
31 13 
32 40 
33 26 
34 12 
35 15 
36 41 
37 24 
38 3 
39 27 
40 7 
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